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Everything that can be invented has been invented.
Charles H. Duell, Director of the U.S.
Patent Office 1899 (recommending that the Patent Office be abolished)
The patent landscape is a minefield.
- Tom Abage, San Francisco Chronicle
January 12, 20001
[T]he ... patent system may... be described as dislocated and being
"out of sync" with the vibrant and explosive advances in science and
technology.
- Kojo Yelpaala, Professor of Law University
of the Pacific, 20002
Designed more than a hundred years ago to meet the.., needs of a
[simpler] economy ... our system of intellectual property rights are an
undifferentiated one-size-fits-all system.
- Lester C. Thurow, Dean Emeritus MIT Sloan
School of Management, 19993
1. Tom Abage, Words and Germs Bait Biotech's Hooks, SAN FRANCISCO
CHRONICLE, Jan. 12, 2000, at D1, cited in Cliff D. Weston, Chilling of the Corn:
Agricultural Biotechnology in the Face of U.S. Patent Law and the Cartagena
Protocol, 4 J. SMALL & EMERGING Bus. L. 377,408 n.229 (2000).
2. Kojo Yelpaala, Owning the Secret of Life: Biotechnology and Property
Rights Revisited, 32 McGEORGE L. REV. 111, 187 (2000).
3. Lester C. Thurow, Poaching Patents, 19 CAL. LAW., Nov. 1999, at 23, cited
in Yelpaala, supra note 2, at 188 n.298. See generally Lester C. Thurow,
Globalization: The Product of a Knowledge Based Economy, ANNALS AM. ACAD.
POL. & SOC. SCI., July 2000, at 19.
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I. INTRODUCTION AND RECENT CURRENT EVENTS
During the last decade, Genetically Modified Crops (GMCs) and the
scientific techniques that inspire them have become commonplace. So,
too, have the controversies. While GMCs are being grown, sold, and
consumed at unprecedented levels - and genetic cloning techniques
have become ubiquitous in scientific research - critics contend that
the economic, social, political, and ecological risks of GMCs are too
great; therefore, GMCs should be more vigorously controlled. On the
other hand, the inertia behind the development and potential benefits
of GMCs are enormous. In fact, the main problem with GMCs is not
the risks they impose, but the ways by which they are inconsistently
and inadequately managed. More specifically, the intellectual
property (IP) rights associated with GMCs are often muddled,
inconsistent, or unclear, leading the interests of key inter-regional,
inter-state, and international constituencies to be either ignored,
misunderstood, or unprotected. Ultimately, IP rights enable the
producers of GMCs to wield an inordinate amount of economic and
political power in dictating the use of GMCs; however, their actions
have gone largely unchecked because of the nature of the IP rights
granted. If the IP rights of GMCs are not managed more effectively -
addressing the unique scientific origins of GMCs and the roles of their
creators - critics' worst fears could come to fruition.
This article highlights the need for a new legal framework for
managing GMC IP interests and suggests five guiding principles for
creating such a framework. In doing so, the article explores the
specific case of Australia, which is currently overhauling its IP system,
and analyzes the case of Monsanto Canada v. Schmeiser, decided by
the Canadian Federal Court in 2002.' Australia's current challenges
are an example of both an inadequate IP system and a failed attempt
to reform and adequately address key problems posed by GMCs.
Furthermore, the case of Monsanto Canada illustrates a decision which
serves as a significantly damaging precedent for the IP law it both
creates and inspires. Ultimately, an effective IP regime must be
international in scope. Indeed, individual countries not only must take
initiatives to meet their own needs, but also must address the
inadequacies of the world's current administrative and legal IP
systems. Countries must recognize IP rights for GMCs and
simultaneously account for the economic, social, ecological, political,
4. Monsanto Canada, Inc., v. Schmeiser, [2002] F.C. 309.
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and international interests that GMCs raise. This task is not simple,
but is an essential prerequisite for a sustainable, ethically viable system
that accommodates GMCs and the scientific technology they inspire.
II. THE GENETICALLY MODIFIED CROP (GMC) DEBATE
A. Context & Background
In many ways, GMCs are nothing new. The romanticization of
sowing seeds and growing plants has existed for literally thousands of
years of recorded history Furthermore, humans have "genetically
modified plants and animals through domestication and controlled
breeding for some ten thousand years with little controversy.",6 In the
early 1970s, scientists developed and refined new biotechnological
techniques which enabled them to transfer genes from one species into
7other species. The seeds of controversy then were sown.
During the 1980s, developments proceeded rapidly. In 1986, the
United States was home to the first patent "covering a genetically
engineered variety of corn with increased nutritional value." 8 This was
followed in 1987 with the successful transplant of a "gene from a
bacterial cell into tomato plants, making the plants resistant to
caterpillars. ''9 In 1989, Australia was the first nation in the world to
approve the sale of a genetically modified organism; Bio-Care
Technology, a company specializing in microbial-based inoculants for
use in agriculture and horticulture,10 introduced the world's first
commercial pesticide, NogallTM, which is essentially a genetically
5. See Paul Healy, Buzz on bee-u-tiful plants, THE MERCURY (Hobart, Austl.),
Nov. 23, 2002, at 44 (observing how farming over the ages has been associated with
romantic ideals).
6. Sabrina Safrin, Treaties in Collision? The Biosafety Protocol and the World
Trade Organization Agreements, 96 AM. J. INT'L L. 606 (2002). See generally
JARED DIAMOND, GUNS, GERMS, AND STEEL: THE FATES OF HUMAN SOCIETIES
(1997) (providing extraordinary insights into the ecological and biological
impetuses which enabled civilizations to develop-and collide-as they did).
7. Safrin, supra note 6, at 606.
8. Theresa Ambrose, The Story So Far, THE AGE, June 16, 1999, at 8.
9. Id.
10. See Bio-Care Technology Pty. Ltd. website, available at http://www.bio-
care.com.au/ (last visited Apr. 29, 2004).
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manipulated bacterium with a long shelf-life." Based on the species
Agrobacterium radiobacter (strain K1026), NogallTm effectively helped
stem the tide "of crown gall disease in stone fruit (peaches, cherries,
apricots, plums, and nectarines), nut trees (e.g., almonds, walnuts, and
pecans), caneberries (boysenberries [and] raspberries), clematis, hops,
kiwifruit, persimmon, [and] roses. 1 2 Five years later, in 1994, Calgene
employed anti-sense RNA technology 3 to produce the first plant
product, the Flavr SavrT Tomato, to reach dining hall tables; it was
11. Additional products produced by Bio-Care Technology include the
following:
(a) Twist Fungus Inoculum (containing Dilospora alopecuri for the biological
control of annual ryegrass toxicity in pastures in Southern Australia), available at
http://www.agrobiologicals.com/products/P1642.htm (last visited Apr. 18, 2004);
(b) Nitrogerm and Nobulaid (inoculents for creating nodulation and nitrogen
fixation in pasture and grain legumes such as lucernes (e.g., alfalfa), clovers, lotus,
lablab, vetches, guar, peas, soybeans, cowpeas, mung beans, lupins, chickpeas, faba
beans, and lentils), available at http://www.agrobiologicals.com/products/
P1643.htm (last visited Apr. 18, 2004);
(c) BioCane Granules (containing Metarhizium anisopliae, strain FI-1045, for the
biological control of the beetle white grub, Dermolepida albohirtum, in sugarcane
in North Queensland), available at http://www.agrobiologicals.com/products/
P1641.htm (last visited Apr. 18, 2004); and
(d) BioGreen Granules (containing Metarhizium anisopliae, strain F001, for the
biological control of the pasture beetle scarab, Adoryphorus couloni, in turf and
pastures in southeastern Australia), available at http://www.agrobiologicals.com/
products/P1640.htm (last visited Apr. 18, 2004); see also http://www.ats.business
.gov.au/ats-members/nogall-control of crown-gal.htm (last visited Apr. 26, 2004)
(providing an overview of Nogall).
12. Agrobiologicals website, available at http://www.agrobiologicals.com
/products/P247.htm (last visited Apr. 18, 2004).
13. In prokaryotes, antisense RNA is known to down-regulate expression of
specific genes. This type of regulatory control has not been observed in higher
eukaryotes, but in frog oocytes and Drosophilia embryos, antisense RNA can
cause decreased expression of target genes. In the tomato, the enzyme
polygalacturonase (PG), encoded by the PG gene, is expressed during ripening. PG
activity causes depolymerization of the pectin fraction of the cell wall, which
results in softening of ripe tomatoes. Theoretically, the introduction of an antisense
PG gene was the expected result in an mRNA that would suppress the expression
of the endogenous PG enzyme, which is what was ultimately achieved in the Flavr
SavrTh tomato. See C. J. S. Smith et al., Antisense RNA inhibition of
polygalacturonase gene expression in transgenic tomatoes, 334 NATURE 724 (1988),
cited by University of Toronto, The Genetics of the Flavr Savr website, available at
http://dragon.zoo.utoronto.ca/-jlm-gmf/TO101A[Enzyme.html (last visited Apr. 18,
2004).
20041
Journal of Contemporary Health Law and Policy [Vol. 20:367
also the first genetically modified food (GMEF) sold in the United
States.14 One year later, Monsanto's NewLeaf® potato" was the first
commercial crop with built-in insect repellant; it included a gene from
the bacterium Bacillus thuringiensis, or BT, engineered to protect it
primarily from the Colorado Beetle and other insect larvae in the
lepidopetera class (e.g., butterflies and moths). 6
The late 1990s brought more technological developments and the
first significant sets of scares and controversies. Given this article's
later discussion of Australia as illustrative of a jurisdiction in need of a
new IP regime, it is worth focusing on particular developments there.
Just months after Australia's approved release of patented Ingard TM
cotton17 (containing a genetic defense to caterpillar attack and the first,
and only, genetically modified crop grown in Australia), it was
discovered that five of twenty major brands of cheddar cheeses had
used genetic engineering to produce the cheeses, though this fact was
not noted on their labels. 8 Consumers reacted by boycotting the
cheeses and, just four months later, the Australian government halted
the sale of all GMFs after an Adelaide-based company, BresaGen,
called for the destruction of cattle which had eaten feed with a
modified growth gene producing leaner meat.' 9 On February 3, 1997,
the Australian government instituted labeling requirements requiring
any products with more than five percent of modified agreements to
14. See U.S. Dept. of Agriculture, NBIAP News Report: Two Views of the
Flavr Savr, available at http://www. accessexcellence.org/AB/BA/TwoViews-of_
FlavrSavr.html (last visited Apr. 29, 2004).
15. Varieties of potatoes are currently widely sold on the market by Monsanto
(designated by a series of codes, including BT-6, SPBT02-05, RBMT21-129,
RBMT21-350, and RBMT22-82). See http://www.mhlw.go.jp/english/topics
/qa/dna/ (last visited Apr. 12, 2004) (detailing information about current strains
being assessed by Japan's Ministry of Health, Labor and Welfare for use in Japan).
16. See W.D. Gelernter & J. T. Trumble, Factors in the Success and Failure of
Microbial Insecticides in Vegetable Crops, 4 INTEGRATED PEST MANAGEMENT
REVIEWs 301 (1999), abstract available at http://www.kluweronline.com
/article.asp?PIPS=254056&PDF=1 (last visited Apr. 17, 2004); see also
http://www2.kenyon.edu/Projects/Agri/ghei01.html (last visited Apr. 14, 2004).
17. The active constituent in this strain of cotton is a subspecies of Bacillus
thuringiensis. The kurstaki delta endotoxin is produced by the CrylA(c) gene and
its controlling sequences. See Gelernter & Trumble, supra note 16, passim. See
generally http://www.monsanto.com.au/images/cotton/labels/ingard.pdf (last
visited Apr. 18, 2004) (displaying the label affixed to bags of the insecticide).
18. Ambrose, supra note 8, at 8.
19. Id.
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obtain approval - on a case-by-case basis - for public consumption.20
Less than two weeks later, on February 14, 1997, Australia prohibited
BT-genetically modified Maize, followed by Luxembourg on March
17, 1997, and the EU required labeling of all products with genetically
modified foodstuffs in early April.2' Only three weeks later, the
United Kingdom's Prince Charles called a complete halt to genetic
manipulations of food, warning that scientists were straying into
"realms that belong to God, and to God alone. 2 2 On June 7, 1998,
Swiss voters overwhelmingly supported a referendum banning all
genetic alterations and patenting of animals."
Despite these controversies, genetic crops have continued to
multiply and a wide range of varieties now exist. Most GMCs
comprise four crops: soya, corn, cotton, and canola;24 and, as Professor
Marsha A. Echols notes, they take one of three forms: (a) basic
TM
agricultural or bulk products (e.g., the long-life Flavr Savr Tomato,
insect-resistant maize, and Roundup Ready TM Soybeans); (b) processed
products with genetically engineered ingredients (e.g., tomato puree
from long-life tomatoes); and (c) genetically engineered foods (e.g.,
chymosin, a vegetarian milk coagulant for cheese). 25 A wide variety of
products currently being developed include "salt-tolerant and drought-
tolerant crops; coloured cotton; plants that make plastic starters; and
plants in which drugs and vaccines are produced."26
Internationally, "the OECD has estimated that more than 1,100 field
trials were conducted with transgenic plants between 1986 and 1992."
2
Furthermore, Monsanto currently owns ninety percent of the world's
20. Id.
21. See Europe Information Service, Genetic Engineering: Labeling Proposals
for GMOs will still 'leave consumers in the dark,' EUROPEAN REPORT, April 5,
1997; see also http://www.american.edu/TED/SOYBEAN.HTM (last visited Apr.
16, 2004) (quoting a Reuters report entitled European Commission Announces New
Labeling Laws dated Apr. 7, 1997).
22. See sources cited supra note 21.
23. See sources cited supra note 21.
24. Adrienne Clarke, Australia Needs to Protect its GM Technology:
Ownership the Key, WEEKLY TIMES, Oct. 9, 2002, at 15.
25. Marsha A. Echols, Food Safety Regulation in the European Union and the
United States: Different Cultures, Different Laws, 4 COLUM. J. EUR. L. 525, 536
nn.51, 53-54 (1998).
26. Adrienne Clarke, Enormous Environmental Benefits in GM Crops,
CANBERRA TIMES, October 10, 2002, at A18.
27. Stevan M. Pepa, International Trade and Emerging Genetic Regulatory
Regimes, 29 LAW & POLY INT'L Bus. 415,423-24 (1998).
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GMCs, charges "technology fees" for its services,28 and is leading the
way in research and development efforts. India, among others, has
fought back with a very loose IP system as a means of encouraging
innovation and allowing its citizens to make use of the technologies
without needing to pay key royalties. The United States Trade
Representative Office, however, used access to U.S. markets as a lever
to induce other countries to follow its lead in protecting IP issues.29 In
so doing, it has suggested that arguments over the efficacy of GMCs
will most likely be addressed in the halls of legislatures enacting IP
regulation, and not laboratories or public rallies.
B. Positive & Negative Implications of GMCs
The potential benefits of GMCs are arguably enormous and pundits
often raise these in response to arguments considering GMCs a threat
to the environment, public health, and the "naturalness" of scientific
endeavors. °  Their arguments fall into seven main categories,
addressing issues related to (a) production, (b) economics, (c) health,
(d) the environment, (e) development, (f) risk, and (g) politics. Each
of these is considered in turn.
The most salient argument for GMCs is that higher quality
foodstuffs can be produced in greater quantities, more than meeting
market demand.31  The main implication of this observation is
decreased hunger, as more food can be produced while protecting
biodiversity. This stems from the fact that land can be used more
efficiently, with currently untouched land protected for future
generations.32 Providing enough food for the world's population has
been deemed the "biggest problem facing the world" this upcoming
28. See Victoria Laurie, Seeds of Revolution, AUSTRALIAN MAGAZINE, Sept.
28, 2002, at 16; see also Exhibit 14, contained in the Appendix (highlighting
Monsanto's business interests, spanning a host of areas).
29. Pepa, supra note 27, at 430.
30. See Enormous Environmental Benefits in GM Crops, supra note 26.
31. See George E.C. York, Global Foods, Local Tastes and Biotechnology: The
New Legal Architecture of International Agricultural Trade, 7 COLUM. J. EUR. L.
423, 429 (2001).
32. See Henrique Freire de Oliveira Souza, Genetically Modified Plants: A
Need for International Regulation, 6 ANN. SURV. INT'L & COMp. L. 129, 174 (2000).
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millennium,33 a comment echoed by followers of David Ricardo in the
early 1800s and those who laud increased crop yields, reduced
dependence on fertilizers, and reduced labor capital in the face of large
population increases. 34
The second and third sets of arguments favoring GMCs address the
economic and health benefits provided by GMCs. Economically, for
example, Roundup Ready TM Soybeans are reported to save farmers
hundreds of millions of dollars annually35 in increased yields and
reduced waste, thus promoting sustainable farming.36 Furthermore,
GMCs can be designed with enhanced nutritional profiles, readily
applicable for developing pharmaceuticals.37 Mortality rates can be
lowered as food production is expanded, simultaneously increasing the
nutritional value of available food." An example is the Golden Rice
developed by the Swiss scientist Ingo Potrykus to help address Vitamin
A deficiencies leading to 250,000 cases of childhood blindness in Asia
and "millions of deaths worldwide each year.,
39
The fourth and fifth sets of reasons for promoting GMCs address
their environmental and developmental benefits. The former stems
directly from the fact that crops can be designed which are resistant to
pests, "drought and frost, able to grow in high alkaline and high metal
soils, able to grow more quickly, and produce higher yields" 40 by
ripening more slowly. Because they often require fewer natural
resources to grow, they also - as noted above - are less taxing on the
environment. This particularly benefits both (a) developing countries
(amassing the majority of GMCs' "developmental" benefits), and (b)
33. Valkerie Mangnall, Enough Food the World's Biggest Problem, Expert
Say[s][sic], AAP NEWSFEED, July 20, 1999. See DAVID RICARDO, PRINCIPLES OF
POLITICAL ECONOMY AND TAXATION passim (Empiricus 2002) (1804).
34. See RICARDO, supra note 33, passim.
35. JANET E. CARPENTER, NATIONAL CENTER FOR FOOD & AGRICULTURAL
POLICY, CASE STUDIES IN BENEFITS AND RISKS OF AGRICULTURAL
BIOTECHNOLOGY: ROUNDUP READY SOYBEANS AND BT FIELD CORN 1, cited in
York, supra note 31, at 429.
36. Press Release, U.S. State Department, U.S. Officials Press Biotechnology
to Fight Hunger (June 11, 2002), available at WESTLAW research ref. no.
25989286.
37. See York, supra note 31, at 430.
38. Julie Teel, Rapporteur's Summary of the Deliberative Forum: Have NGOs
Distorted or Illuminated the Benefits and Hazards of Genetically Modified
Organisms?, 13 COLO. J. INT'L ENVTL. L. & POL'Y 137, 146 (2002).
39. Id. at 147.
40. Id. at 146.
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research scientists ("developing" new scientific ideas and experimental
processes).
All these benefits are enhanced by a sixth set of arguments holding
that GMCs carry very low risks. Two years ago, 3,200 scientists signed
an on-line declaration drafted by AgBio World entitled "Scientists in
Support of Agricultural Biotechnology," among them Nobel Laureates
Norman Borlaug, James Watson, Paul Berg, Peter Doherty, Paul
Boyer, and the 1998 National Medal of Science Recipient, Bruce
Ames.4 ' This fact does not independently guarantee that GMCs are
safe, particularly in light of the fact the declaration is decidedly
partisan, though it does suggest that individuals with noted scientific
achievement have voiced their feelings that the use of GMCs does not
portend disaster.
Finally, there are the socio-political benefits. One cannot understate
the degree to which public health issues have come to be a major
geopolitical force. The case for fighting AIDS is the most striking
example, as evidenced by U.S. Secretary of State Colin Powell's calling
for strong HIV/AIDS prevention measures in developing countries as
a key element of National Security.42 The role of developing GMCs in
the interests of facilitating exchanges of views among various groups,
particularly non-governmental organizations (NGOs), is also helpful.
NGOs not only can provide information about GMCs, but encourage
public participation in their creation and oversight; oversee the
creation of new laws; influence corporate behavior (ideally positively);
and oversee compliance with the law.43
41. See AgBioWorld.org, Petition, Scientists in Support of Agricultural
Biotechnology, available at http://www.agbioworld.org/declaration/petition/
petition.php (last visited Apr. 19, 2004); list of Nobel Laureate signatories available
at http://www.agbioworld. org/declaration/nobelwinners.html (last visited Apr. 19,
2004).
42. See Human Rights Campaign, HRC Encouraged by Colin Powell's
Comments on MTV Supporting Strong HIV/AIDS Prevention Measures, available
at http://www.hrc.org/Content/ContentGroups/NewsReleases/2002/HRC_
Encouraged-byColin (last visited Feb 22,2004).
43. See Teel, supra note 38, at 148-156. But consider the fact that NGOs also
can be seen as distorting the debate by (a) not representing the public, (b)
overestimating health and environmental risks, and (c) responding inconsistently
to regulatory concerns. Id.
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The risks of GMCs often appear to significantly outweigh these
benefits. In fact, GMCs have come to be seen as more "periah[s] than
messiah[s]" 44 as the unintended risks they do impose are amplified,
since the world population is expected to grow from 5.8 billion today
to 8.4 billion by 2025, and this growth will require a doubling of current
food production.45 While gene alternations may thus make such
growth possible,4 they are also harbingers of disaster. There are four
main problem areas cited vis-A-vis GMCs, with the central theme that
"when discrepancies between scientific consensus and government
policy result in unwanted consequences, the blame is often placed," for
better or for worse, "directly on GM crop technology itself.
4 7
The first set of concerns stem from the inevitable fact that GMCs
cannot be managed. Indeed, once they are "released" into the
environment, the consequences of their uncontrolled reproduction in
the face of decreased biodiversity cannot be predicted. This can take
many forms, the first of which are the crops' unknown side effects.
Nitrogen fixing in high yielding crops is one example, 48 as are the
migration of trans-genes into non-target organisms via inbreeding,
assorted mating, and outcrossing - namely, the processes by which
domesticated plants hybridize with wild relatives, thereby producing• • 49
new varieties. The main concern is that while "outcrossing is a
common occurrence in conventional agronomy, outcrossing in
transgenic plants may occur at significantly higher rates."5° The New
44. Editorial Staff, Food Fight, BUSINEss REVIEW WEEKLY, June 9, 2000, at 98.
45. Editorial staff, World's Double Trouble, WEEKLY TIMES, Oct. 21, 1998, at 3.
46. Id.
47. Honor Hsin, Bittersweet Harvest: The Debate Over Genetically Modified
Crops, 24 HARV. INT'L REV. 38 (2002).
48. Mae-Wan Ho, Perils and Promises of Genetically Modified Foods,
Prepared on behalf of Greenpeace International, November, 1996, at 1, available at
http://archive.greenpeace.org/geneng/reports/food/food002.htm (last visited Apr.
18, 2004), cited in York, supra note 31, at 432 n.54.
49. ANTHONY J. F. GRIFFITHS ET AL., AN INTRODUCTION TO GENETIC
ANALYSIS (7' ed.) 726 passim (2000) [hereinafter "GENETIC ANALYsIS"]. This is a
particular concern in countries with significantly large amounts of transgenic crops.
See Exhibit 6, contained in the Appendix (summarizing the leading countries with
transgenic crops today).
50. Holly Saigo, Note, Agricultural Biotechnology and the Negotiation of the
Biosafety Protocol, 12 GEO. INT'L ENVTL. L. REV. 779, 787 (2000), cited in George
Van Cleve, Regulating Environmental and Safety Hazards of Agricultural
Biotechnology for a Sustainable World, 9 WASH. U. J. L. & POL'Y 245, 258 n.40
(2002). For a more detailed discussion, see Joy Bergelson et al., Promiscuity in
Transgenic Plants, 395 NATURE 25 n.40 (2002) (reporting the results of a field
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York Times reported on October 2, 2001, for example, that Maize
growing in fifteen different locations in Mexico contained genetically
engineered genes without the growers' knowledge.5 This mirrored the
StarLink® scare of 2000, when foodstuffs containing StarLink®corn,
genetically modified to produce a bacterial protein Cry9c creating
12Bacillus thuringiensis (Bt) insect resistance, were discovered on
supermarket shelves. This resulted in a nationwide recall of 300 kinds
of corn-based foods.53 The concerns that Cry9c was an allergen
stemmed from a range of clear scientific facts, including that it (a) "was
relatively resistant to acid treatment;" (b) "was relatively resistant to
breakdown by digestive enzymes;" (c) in the "general molecular
weight range for an allergen (i.e., 10-70 kd);" (d) had a "native protein
which was probably a glycoprotein;" (e) induced an "immunologic
response in Brown Norway rats;" and (f) could "be found intact in the
bloodstream after oral feeding in the rat model."54 For these purposes,
StarLink® was originally only approved for "animal feed due to
concerns it might cause allergic reactions in humans."55 The EPA later
experiment in which Arabidopsis thaliana mutants for the Csrl-1 allele of
acetolactate synthase-conferring resistance to the herbicide chlorsulphuron-
were compared with transgenic plants; "a survey of approximately 100,000 seeds
showed that the per-plant outcrossing rate was 0.30% for mutant fathers and
5.98% for transgenic fathers, indicating that transgenic A. thaliana were roughly
twenty times more likely to outcross than ordinary mutants."). The authors note
that they did not know the underlying genetic mechanism, though highlight that
"genetic engineering can substantially increase the probability of transgene escape,
even in a species considered to be almost completely selfing." This is significant
cause for concern since it suggests transgenes can escape even in the most
elemental circumstances (i.e., a completely selfing species).
51. Carol K. Yoon, Genetic Modification Taints Corn in Mexico, N.Y. TIMES,
Oct. 2, 2001, at F7, cited in Van Cleve, supra note 50, at 288 n.153.
52. See infra Exhibit 10, listing the key properties and methods used to produce
StarLink® corn.
53. See Teel, supra note 38, at 141 n.14 (citing Andrew Pollack, 1999 Survey on
Gene-Altered Corn Disclosed Some Improper Uses, N.Y. TIMES, Sept. 4, 2001, at
C2; Marc Kaufman, Biotech Corn Fuels a Recall: Unapproved Variety Used in Taco
Shells, WASH. POST, Sept. 23, 2000, at Al.).
54. Institute of Food Technologies, Questions about Starlink®, available at
http://aggiehorticulture.tamu.edu/extension/newsletters/foodproc/febOl/art3feb.ht
ml (last visited Apr. 10, 2004).
55. Randy Fabi, Japan Finds StarLink Corn in US Cargo, Reuters, Dec. 27,
2001, reproduced at the Organic Consumers Association Website, available at
http://www.organicconsumers.org/ge/010403-starlink_corn.cfm (last modified Apr,
18, 2004).
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noted that wet-milling corn could remove virtually all of the StarLink®
protein from products made for human food16 and that StarLink® corn
would in any event be essentially eliminated from the corn grain
supply by 2002.17 The short-term problem was ultimately solved,
though the far broader problem of unpredictability remained.
These fears of unpredictability - and ultimately unmanageability -
are mirrored in the second major set of concerns about GMCs
addressing broader environmental issues, particularly with regard to
the unintended effects of GMOs (often linked with GMCs) on
humans. Indeed, having general side effects is one concern, though the
"unintended consequences in the ecosystems in which" the GMOs
reside is another matter.58 The worry is that the negative effects of
GMCs will transcend their unintended consequences on humans and
damage the broader ecosystem within which they coexist.
When it comes to the specific effects of GMCs on humans, there are
several worries. The first relates to the way in which lives will be
significantly affected if allergic responses are either initiated or
exacerbated by ingestion of GMCs. Soybeans, for example, are low in
the amino acids methionine 59 and cysteine, so people whose diets are
bean-based face a nutritional deficiency.61 Researchers responded by
transferring a gene from Brazil nuts which codes for large amounts of
these acids. While seen as a great opportunity, these researchers were
ultimately disappointed by the fact that the protein was also an
56. See U.S. ENVIRONMENTAL PROTECTION AGENCY, WHITE PAPER ON THE
POSSIBLE PRESENCE OF CRY9C PROTEIN IN PROCESSED HUMAN FOODS MADE
FROM FOOD FRACTIONS PRODUCED THROUGH THE WET MILLING OF CORN (2002),
available at http://www.epa.gov/scipoly/ sap/2001/july/wetmilling.pdf (last visited
Apr. 18, 2004); see also Exhibits 11-12, contained in the Appendix (illustrating the
benefits of wet-milling)
57. See sources cited supra note 56.
58. York, supra note 31, at 433.
59. The linear structural formula for methionine is CH3-S-(CH2)2-CH(NH2)-
COOH.
60. The linear structural formula for cysteine is HS-CH2-CH(NH2)-COOH.
61. ALLEN MCHUGHEN, PANDORA'S PICNIC BASKET: THE POTENTIAL AND
HAZARDS OF GENETICALLY MODIFIED FOODS 120 (2000), cited in Kurt Buechle,
The Great, Global Promise of Genetically Modified Organisms: Overcoming Fear,
Misconceptions, and the Cartagena Protocol on Biosafety, 9 IND. J. GLOBAL LEGAL
STUD. 283, 293 n.77 (2001). Consider also the case for new GMCs providing
antibiotic resistance (given the fact that plants which receive a gene of interest also
contain antibiotic resistant gene and there is concern this gene can be transferred
to humans).
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allergen. A second example is the case of antibiotics, whereby plants
with genes of interest containing antibiotic resistant genes (for the
purpose of assays) might transfer this resistance to humans and reduce
the efficacy of antibiotics for treating humans. This is feared to
stimulate the evolution of resistant plants and insects from overusing
genetically modified seeds. 63
The third set of concerns stem from the legal and socio-economic
consequences of GMCs and integrate the concepts of property
ownership and economic power. First, there is the fundamental
concern that GMCs are goods which are inherently 'public' in nature,
but are now being patented by individuals and corporations. In this
regard, the biggest problem with GMCs is not the GMCs themselves,
but the "corporate attempts to dominate world markets by owning the
technology." 64 The existence of patents and IP protections thus impose
costs on society because the patentees are "able to charge monopoly
prices" for their patented products or for "products made with [a]...
patented process. ' 65 This may allow patentees to "recoup" their initial
research investments, 66 but puts consumers at a decided disadvantage,
particularly in developing countries. 67 The fact that companies can
"sit" on their patents, effectively failing to exploit them and denying
others the opportunity to do so, may cause the most concern in a
society which can yield powerful insights from the technology.68 Also,
IP rights to genes create a series of economic incentives compelling
manufacturers to produce GMCs for the market very quickly
regardless of the risks. Newly patented genes, it is argued, should not
be patentable 69 for any reason.
The fourth and final area addresses the more opaque issue of culture
and the ways in which GMCs can deleteriously affect and change
62. Id.
63. Sara M. Dunn, From Flav'r Sav'r to Environmental Saver? Biotechnology
and the Future of Agriculture, International Trade, and the Environment, 9 COLO. J.
INT'L ENVTL. L. & POL'Y 145, 155 (1998).
64. Editors, Who Owns Wins, TASMANIAN COUNTRY (Austl.), Sept. 27, 2002, at
1.
65. STAINFORTH RICKETSON, THE LAW OF INTELLECTUAL PROPERTY 46.32,
at 871 (1984).
66. See infra Exhibit 5, illustrating the huge investment costs associated with
GMCs- and their increased use - in the world today.
67. York, supra note 31, at 429.
68. Id.
69. Mark Thornton, Seeds of Destruction, COURIER MAIL (Austl.), Jun. 23,
2001, at 31.
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cultures. Some cuisines, for example, may be predicated on
"naturalness,"70 while in other cultures food represents a "symbol of
belonging, [and] code of social or cultural recognition.",71 This serves
to explain why "international commerce in foods and ingredients has
existed throughout human history, [though] local traditions and
attitudes about diet persist. 72 It has often been these factors which
enable NGOs and the arguably "motley assemblage of environmental
activists, farmers, scientists, and consumer groups" to publicize
successfully their points against GMCs and "disrupt the powerful and
pervasive multinational industry of agricultural biotechnology.,
73
Public opinion is molded by many forces, but particularly by NGOs.
Often, this molding results in emotive responses to ensuing problems,
divorced from scientific realities.74
In these regards, the seemingly chaotic responses to GMCs make
more sense. Europe's digging up thousands of hectares of crops
inadvertently planted with GM seeds,75 as well an array of extensive
U.S. federal guidelines allowing regulators to "question and/or halt
70. See Echols, supra note 25, at 525.
71. Sophie Bessis, Foreword to MILLE ET UNE BOUCHES: CUISINES ET
IDENTITIS CULTURELLES [A Thousand and One Mouths: Cuisine and Cultural
Identity] 12 (Sophie Bessis ed., 1995) quoted in Echols, supra note 25, at 525, and
cited in York, supra note 31, at 423 n.1.
72. Echols, supra note 25, at 525.
73. Teel, supra note 38, at 137.
74. See Thomas R. DeGregori, NGOs, Transgenic Food, Globalization, and
Conservation, 13 COLO. J. INT'L ENVTL. L. & POL'Y 115, 115-16 (2002). DeGregori
writes,
The organizations advance their agenda through emotional pleas, fear
tactics, and propaganda, supported by little sound scientific or factual data
... embark[ing] on neo-colonialism in a form of ecological colonialism...
by seek[ing] control over the habitat or wildlife resources in developing
countries . . .attacking modernization and industrialization .... While
NGOs frequently decry the evils of 'globalization' ... the organizations
are no less global in their agendas.
Id. at 116.
75. See Food Fight, supra note 44, at 98. Noting that
30,000 hectares of land was reported to have been planted with Canadian
canola seed by seed giant Advanta, into which a small volume of
genetically modified canola or rapeseed had been mixed. It had
accounted for less than 1% of the seeds, but the National Farmers Union
and Scottish Agricultural Minister advised farmers to dig them up because
they were unsaleable [sic] in Europe.
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development of a biotech plant variety ' 76 if one of a large array of
authorizations does not yield a clean "bill of health,",77 all result from
GMC-based fears.
C. Recent Scientific & Political Developments
There have been four main sets of responses to these concerns in the
hopes of realizing the benefits of GMCs: (a) labeling standards; (b)
strong, mandatory regulations; (c) international agreements; and (d)
76. AMERICAN CROP PROTECTION ASSOCIATION, PLANT BIOTECHNOLOGY
REGULATION: SCIENCE BASED AND CONSUMER ACCESSIBLE FROM PLOW TO PLATE
1 (2002), cited in York, supra note 31, at 439 n.99.
77. These authorizations include:
(1) Biosafety Committee Review: Following NIH guidelines, an advisory
group evaluates the plant for potential health and environmental risks;
(2) Greenhouse Approval: USDA determines the adequacy of research
facilities for biotechnology development;
(3) Field Trial Authorization: GM crop developers must receive USDA
approval for field trials and submit summary reports;
(4) Seed Transport Authorization: USDA oversees the shipment of GM
seeds from facilities to the field trial sites;
(5) Commercialization Permission: APHIS experts must review all field
trial studies before a GM crop can be grown, tested or used for traditional
plant breeding without further USDA action;
(6) Experimental Use Permit Approval: EPA must grant an experimental
use permit (EUP) for test of 10 acres or more;
(7) Food Tolerance or Exemption: EPA examines the product
characterization, toxicology, allergenicity, non-target organisms,
environmental impact and pest resistance to establish limits on the
amount of pest-control proteins in GM foods;
(8) Product Registration: EPA reviews all relevant environmental and
toxicological studies before deciding to register a GM product;
(9) Review Process: FDA's review procedure is in the process of moving
from a voluntary, albeit universally used, consultation mechanism to a
mandatory four-month-prior-to-release notification mechanism requiring
a showing by the introducing party of substantial equivalence; and
(10) Post-Commercialization Review: All three regulators have the
authority to demand the immediate removal from the marketplace of any
product in the case of new and valid data indicating a question of safety
for consumers or the environment.
Id. at 2-4, cited in York, supra note 31, at 439 n.100.
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recommended, largely unsupervised guidelines."8 Unfortunately, none
of these can adequately suffice, largely stemming from the fact that
they each try to address a part of the issue without considering the
problem in its entirety. When one considers the Food and Agriculture
Organization's key guiding principles iterated in the late 1990s, one
can better envisage the enormity of the task. These included
(a) the sustainable use of plant genetic resources is essential for
increasing agricultural productivity, and this fact can contribute
not only to food security but also to natural development,
allowing both the alleviation of poverty and starvation;
(b) modern agriculture is the most important cause of loss of
genetic diversity, and the loss of diversity increases the
possibility of crop losses; and
(c) much needs to be done, and done locally... [and] in the long
term the preparation of a Report on the State of Agricultural
Diversity [globally] should be considered.79
With these in mind, the first and most common governmental
response has been labeling regimes which stipulate that if a food
contains GMCs, this fact should be noted and the market can decide if
genetic modifications should be rewarded. Consumers will be able to
decide if the benefits outweigh the costs. An example of a labeling
scheme includes a proposal of the FDA for GM producers to label
their products with certain information if the absence of the
information may
(1) pose special health or environmental risks (e.g. [allergens,
toxins and] ... protein products used in very low calorie diets);
(2) mislead the consumer in light of other statements made on
the label (e.g. requirement for quantitative nutrient information
when certain nutrient content claims are made about a product);
or
(3) [lead consumers to] . . . assume that a food, because it is
similar to another food, has nutritional, organoleptic, or
78. This list (assembled by this author) parallels several others, such as that
proposed by Echols, supra note 25, passim, listing five key responses, namely: (a)
labeling, (b) treatment, (c) testing and certification, (d) destruction, and (e) bans.
79. Souza, supra note 32, at 147 (citing FOOD AND AGRICULTURE
ORGANIZATION (FAO), REPORT ON THE STATE OF THE WORLD'S PLANT GENETIC
RESOURCES FOR FOOD AND AGRICULTURE-PREPARED FOR THE INTERNATIONAL
TECHNICAL CONFERENCE ON PLANT GENETIC RESOURCES 6, 8, 13, 15 (1996))
[hereinafter FAO].
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functional characteristics of the food it resembles when in fact it
does not (e.g. reduced fat margarine not suitable for frying). 80
These guidelines have parallels in other jurisdictions, though are often
inconsistent, leading to the fact that labeling standards vary from place
to place and there is no consistent labeling protocol.8' Probably the
most controversial step in these regards was that taken by an E.U.
Directive in October 1999 requiring the "mandatory labeling of novel
food products containing more than one percent engineered DNA or
protein content (and insinuated associated food safety risks based on
the 'precautionary principle')," discussed in greater detail below.
A second major set of responses has been to legislate, and to
legislate rigorously. In 1996, for example, the EU rejected the use of
genetically modified Maize corn seed, arguing that the convention on
Biological Diversity was too weak and it had to take matters into its
own hands.83 This was largely in response to companies producing
products which were not just resistant to pests, but were sterile.
"Terminator genes," as they were called, had been originally
developed by the USDA at a comparatively marginal cost of just
under $250,000 in cooperation with Delta and Pin Land Company, the
largest producer of cotton seeds in the United States with a seventy-
three percent market share.5
A third major route for managing GMCs has involved relying on
international agreements. Article XX(b) of the General Agreement
on Tariffs and Trade (GATT) allows governments to enact trade
80. Press Release, U.S. Food and Drug Administration, Guidance for Industry:
Voluntary Labeling Indicating Whether Foods Have or Have Not Been Developed
Using Bioengineering, Draft Guidance 2 (January, 2001) cited in York, supra note
31, at 441 n.109.
81. Matthew Franken, Fear of Frankenfoods: A Better Labeling Standard for
Genetically Modified Foods, 1 MINN. INTELL. PROP. REV. 153 (2000).
82. Briefing Paper for the June 13, 2000 meeting of the ACIEP, Advisory
Committee on International Economic Policy (ACIEP), U.S. Department of State
24, cited by York, supra note 31, 453 n.178; see also infra Exhibit 15, highlighting
how most countries about to join the E.U. do not want GM products distributed
within their borders.
83. Land and Resource Management Division of the University of Colorado,
Biotechnology and Biodiversity, COLO. J. INT'L ENVTL. L. & POL'Y 47 (1996).
84. Forum Proceedings, A Greener Shade of Crimson: Law & the Environment
Alumni Forum, 24 HARV. ENVTL. L. REV. 317,324 (2000).
85. Nathan A. Busch, Jack and the Beanstalk: Property Rights in Genetically
Modified Plants, 3 MINN. INTELL. PROP. REV. 1,121 nn.470-472 (2002).
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barriers "necessary to protect human, animal, or plant life or health."'
More specifically, the International Biosafety Protocol approved in
2000 by representatives of 130 countries regulates the international
trade of genetically modified organisms (GMOs).' The trade
regulations in the Biosafety Protocol mirrors principles first contained
in the Convention on Biological Diversity passed in 1992, 88 as well as
the United Nations Convention on Biodiversity. The latter describes
biodiversity as having an "intrinsic value" beyond its "ecological,
genetic, social, economic, scientific, education [sic], cultural,
recreation, and aesthetic values." 89  These principles have thus
informed the EU's approach to observing the rights of its member
states to GMC protection by allowing any country to bar GMCs on the
basis of any reasonable fears which the country might have relating to
such crops. This EU approach has come to be known as the
"precautionary principle," referenced above.90 Though its import lies
in provisions which allow it to be used with the force of law,9' the
precautionary principle is arguably on weak ground because of (a)
regional differences in sentiments toward GM foods, (b) myths and
poor reporting, (c) anti-biotech activism, and (d) a lack of a clear way
to disseminate knowledge, understanding, and acceptance of new
technological developments. 92
The fourth and final approach has been recommending guidelines
for GMC producers to follow, but which governments would not
86. York, supra note 31, at 456.
87. See Transgenic Crops Resource Guide, available at http://www.colostate
.edu/programs/lifesciences/ TransgenicCrops/ (last visited Apr. 18, 2004).
88. Convention on Biological Diversity, available at http://www.biodiv.org (last
visited Apr. 18, 2004).
89. United Nations Conference on Environment and Development, preamble,
June 5, 1992, S. Treaty Doc. No. 20 (1993), reprinted in 31 I.L.M. 818, 922, cited in
Judy J. Kim, Out of the Lab and Into the Field: Harmonization of Deliberate
Release Regulations for Genetically Modified Organisms, 16 FORDHAM INT'L L. J.
1160, 1185, (1993).
90. See http://www.biotech-info.net/precautionary.html (last visited Apr. 14,
2004) (providing an overview of the precautionary principle, its history, and its
current applications in political, social, and environmental arenas).
91. See Communication from the Commission on the Precautionary Principle,
Commission of the European Communities 2 (February 2, 2000), cited in York,
supra note 31, at 444 n.125.
92. Buechle, supra note 61, at 300-305 (utilizing these four items as subheaders
within his article to discuss the problems with the precautionary principle).
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directly oversee. The U.S.-E.U. Biotechnology Consultative Forum,93
for example, recommended:
(1) mandatory pre-market testing for all GMCs,
(2) the refinement of the substantial equivalence concept,
(3) the development and implementation of GMO tracing
technology,
(4) the fulfillment of a reasonable certainty of safety threshold
prior to the use of risk-benefit analysis,
(5) a risk assessment regime whereby regulators should act
proactively on the side of safety,
(6) the creation of a content-based mandatory labeling
requirements for products derived from GMOs, and
(7) the implementation of the Cartagena Protocol on
Biosafety. 94
The idea is that NGOs would, as referenced above, act as enforcers
and help ensure that the market manages itself independent of
external regulation.
For the most part, these efforts have born little fruit. Not only have
many laws gone unrecognized - or been simply ignored - but the
power of GMC producers has flummoxed even their greatest critics as
IP rights have essentially dictated what is made, by whom, and when.
Current rules in the United States, for example, state that farmers
must leave twenty percent of their crops outside the corn belt to
conventional corn, though only seventy-one percent of farmers follow
the rule despite the fact ninety percent claim to know or follow it.95
Current contracts for food production, as well, are often bogged down
with extraordinary details, making it practically impossible for every
item to be addressed, particularly with regards to export concerns.9
93. See U.S.-E.U. Biotechnology Consultative Forum, Final Report (December
2000), available at http://www.usembassy.it/pdf/other/biotech.pdf (last visited Apr.
12, 2004). See also U.S. Department of State: Office of the Spokesman, U.S. and
E. U. Establish Biotechnology Consultative Forum, U.S. Mission to the European
Union (June 7, 2000), available at http://www. useu.be/ISSUES/biotO6O7.html (last
visited April 18, 2004).
94. Fact Sheet: Report of the U.S.-E.U. Biotechnology Consultative Forum,
U.S. Department of State 2 (December 19, 2000), cited in York, supra note 31, at
464 n.231.
95. Marc Lappe, Biotechnology and Agriculture, 10 MSU-DCL J. INT'L L. 39,
43-44 (2001).
96. See Illinois Law & Agribusiness Association, Agricultural Production and
Marketing Contracts, IL&A IL-CLE 6-1 (2001).
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There is also the fact that the Biosafety Protocol "does not apply to the
inanimate products of living modified organisms such as corn cereal or
soybean oil that might be made from genetically modified corn or
soybeans," ' rendering key parts of the Protocol largely moot.
98
Monsanto, the largest producer of GMCs, even once refused to submit
to a labeling regime,9 leading U.S. Trade Representative Robert
Zoellick to use his "first major interview to accuse ... companies of
putting at risk the whole intellectual property rights system."' °
Indeed, it would appear that Mary Lynne Kupchella's argument that
"[w]ith proper regulation, biotechnology can save biodiversity and
solve numerous other environmental concerns ' '° is not as simple as
she makes it seem. There are serious concerns over the decreasing
access to new discoveries as the line between fundamental research
and applied research has gotten thinner.10
In essence, the core of the problem is improperly managed and
mediated IP systems. Adrienne Clarke, Professor at the University of
Melbourne, has noted explicitly that "intellectual ownership, not
health concerns, is the real danger associated with GM foods,"1 3 and
the main risk is of companies' patent rights overcoming farmers'
97. Safrin, supra note 6, at 608 (emphasis added).
98. See Cartagena Protocol on Biosafety to the Convention on Biological
Diversity, Jan. 29, 2000, 39 I.L.M. 1027 (2000), available at http://www.biodiv.org
(last visited Apr. 27, 2004) [hereinafter "Protocol"]. Key sections of the Protocol
address (a) requirements for commodities (i.e., requiring parties to create a
Biosafety Clearinghouse with information about products); (b) "Precaution" ideas
(see discussion in the text); (c) Documentation (i.e., shipping different types of
LMOs, identifying identities and relevant traits of LMOs); and (d) trade with
nonparties (i.e., one needs to be party to the Convention on Biological Diversity
before joining the Protocol).
99. The editors of the Australian Financial Review, commenting on this
development, wrote that "by refusing to submit to a labeling regime, Monsanto
had effectively cut its own throat." Editorial staff, The Growing GM and Drug
Disaster, AUSTRALIAN FINANCIAL REVIEW, Mar. 22, 2001, at 41 [hereinafter
"Growing Disaster"].
100. Id.
101. Mary Lynne Kupchella, Agricultural Biotechnology: Why it Can Save the
Environment and Developing Nations, But May Never Get a Chance, 25 WM. &
MARY ENVTL. L. & POL'Y REV. 721 (2001).
102. See Kenneth W. Dam, Intellectual Property in an Age of Software and
Biotechnology, in CHICAGO LECTURES IN LAW AND ECONOMICS 113, 114-116 (Eric
A. Posner ed., 2000), cited in Yelpaala, supra note 2, at 212 n.374.
103. Clarke, supra note 24.
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rights. 1°4 Indeed, there are benefits to GMCs, such as crops grown to
produce proteins instead of traditional fruit or fiber.1 5 But the outcry
over Monsanto's "terminator seed," which could be seen as an
unprecedented self-enforcing patent, seemed to give too much control
to one single entity over both the farmers and the environment it was
seeking to influence and control.' °6 There is no doubt that the "gene
genie," freed from its bottle, has continued "promising to grant wishes
to everyone" ' while letting alarmist responses go unabated'o° and
increasing calls to "go organic.""" The press has posited the argument
that the future leading countries of the world will be those that let
people come to "patent their ideas and take a cut every time someone
else uses them."'10 This, however, remains to be seen.
D. Case Study: Australia
Australia is an excellent case study for assessing alternative IP
regimes which could better address these concerns. International and
domestic critics alike have cited Australia's need to "get its house in
order" with regard to IP issues. United States government officials, in
fact, have specifically "renew[ed] [their] complaints of sloppy
Australian protection of intellectual property rights, '.. and public
104. See Laurie, supra note 28.
105. See Paul Parkinson, Future Farms, COURIER MAIL, Jul. 16, 2002, at H02
(noting the discovery at the Queensland Institute of Technology of INPACT (In-
Plant Activation) - in which one of a plant's protein-producing genes is replaced
with a gene "trained" to create the desired proteins instead.)
106. See Karen Charman, Genetically Engineered Food: Promises & Perils,
MOTHER EARTH NEWS, Oct./Nov. 2002, at 74, 76 (writing how terminator seeds
continue "to spark outrage throughout the world").
107. Editorial Staff, Harnessing the Gene Genie, PERSONAL INVESTOR, Sept. 1,
2000, at 40 [hereinafter "Gene Genie"].
108. Consider, as a case in point, the alarmist responses to Australian Natural
Foods (ANF) labeling its soymilk as "free from genetically modified soybeans and
soy protein isolate." James Button, Guess Who's Coming to Dinner?, THE AGE,
Jan. 3, 1998, at 1.
109. Monica Jackson, Go Organic, Suzuki Says, WEEKLY TIMES, Mar. 1, 2000, at
26.
110. Simon Collins, Smart Shall Inherit the Earth, NEW ZEALAND HERALD, Feb.
20, 2003, available at http://www.nzherald.co.nz/storydisplay.cfm?thesection=news
&thesubsection=&storylD--3147263&reportlD=812597 (last visited Apr. 16,
2004).
111. Editorial staff, US Slams Australian Bans, AUSTRALIAN FINANCIAL
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interest critics have called for "corporate ownership of intellectual
property rights" in Australia to be "watched.""' 2 Critics of Australia's
government note that Australia's problem is a need for an IP regime
where IP "can be protected, developed and traded from Australia"
because too often the country has "sold the rights to publicly funded
research at a very early stage to get paltry returns.""' 3 Economists
would likely cite the need for a system which accounts for Australia's
comparatively small economy (mirroring its small population)."'
Australia is unique in having (a) a small population with high average
incomes; (b) large agricultural and mining sectors which are highly
competitive and export oriented; (c) a developed manufacturing sector
highly protected and highly concentrated; (d) a large service sector
employing seventy percent of labor force; (e) foreign investment as a
major influence on economic development; (f) major sectors with
oligopolistic industry structures; and (g) status as a heavy net importer
of technology (shared by all less developed countries)."5 These points
lead to a set of interests which should be arguably integrated into an IP
system for GMCs.
The Constitution of the Commonwealth of Australia charges the
Parliament with overseeing "[c]opyrights, patents of inventions and
designs, and trademarks.""' 6 Arguments have thus been levied that the
High Court needs to transcend its current approaches to interpreting
this law - which have been quite literal"7 - and instead pursue a
broader approach characterized by a more purposive rationale of the
Constitution's provisions (i.e., focusing on the framers' intents)."8 This
would allow for more creative solutions vis-A-vis novel regulations and
REVIEW, Apr. 2, 2002, at 8.
112. Paul McIntyre, Food for Thought in Cause of the Foot and Mouth Crisis,
THE AUSTRALIAN, Mar. 22, 2001, at M8.
113. Clarke, supra note 24 (emphasis added).
114. For more information, see the CIA WORLD FACTBOOK ON AUSTRALIA,
available at http://www.cia.gov/cia/publications/factbook/geos/as.html (last visited
Apr. 17, 2004).
115. RICKETSON, supra note 65, at 871; see also infra Exhibit 1, illustrating that
Australia is also the least densely populated country on earth.
116. AUSTL. CONST., § 51 (xviii).
117. See Atty. General for N. S. W. v. Brewery Employds Union of N. S. W.
[Union Label Case] (1908) 6 CLR 469, 521, 533-535, cited in Geraldine Chin,
Technological Change and the Australian Constitution, 24 MELB. U. L. REV. 609,
626 n.126 (2000).
118. See, e.g., The King v. Brislan, Ex parte Williams (1935) 54 CLR 262, 282-3,
cited by Chin, supra note 117, at 626 n.127.
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approaches to managing IP for GMCs. To date, the main set of
provisions which have governed IP interests is contained in the Patents
Amendment Act 1979 (Cth). One of the main problems cited soon
after the legislation passed, however, was the fact that it applied the
same sets of standards to all types of patents and, in particular, petty
versus regular patents (i.e., requiring an "inventive step" approach, the
importance of which will be discussed in greater detail below)." 9
These were later amended with the Patents Act 1990 (Cth)
Most recently, Australia sought to accommodate the unique needs
of GMCs by creating an "Innovative Patent System" in 1997 to
encourage "individuals and small to medium sized businesses to realize
their good ideas.' ' 21 This stemmed from a review by the Advisory
Council on Intellectual Property (ACIP), with the legislation
ultimately watering down the "standard of inventiveness' ' 22 so that
protection would be "withheld if the claimed invention varie[d] from
previously publicly available articles, products or processes 'only in
ways which make no substantial contribution to the effect of the
product or working of the article or process." '23 The idea was that the
approval of new, novel IP patent applications needed to be
streamlined and this was the most effective way to do so.
Subsequent events proved this approach largely unworkable for IP
and biotechnology inventions. In May 1999, the Australian
government formed a new agency, Biotechnology Australia, to address
biotechnology and GMFs along with an Interim Office of the Gene
Technology Regulator to administer a voluntary labeling code until
119. See Patents Amendment (Innovations Patents) Act, 1979, 6 (Austl.),
available at http://www.austlii.edu.au/au/legis/cth/consol-act/papa2000400/ (last
visited Apr. 10, 2004).
120. For a comprehensive discussion of the Patent Act 1990 (Cth), see JILL
MCKEOUGH, INTELLECTUAL PROPERTY: COMMENTARY AND MATERIALS (4th ed.
1992). See generally JILL MCKEOUGH & ANDREW STEWART, INTELLECTUAL
PROPERTY IN AUSTRALIA (2nd ed. 1994); COLIN GOLVAN, AN INTRODUCTION TO
INTELLECUTAL PROPERTY LAW (1992).
121. Mark D. Janis, Second Tier Patent Protection, 40 HARV. INT'L L. J. 151, 171
n.111 (1999). See generally CHRISTOPHER ARUP, INNOVATION, POLICY, AND LAW:
AUSTRALIA AND THE INTERNATIONAL HIGH TECHNOLOGY ECONOMY (1993)
(discussing the need for innovation for patenting genetic discoveries).
122. See Roland Liesegang, German Utility Models after the 1990 Reform Act, 20
AIPLA Q.J. 1, 4-5 (1992), cited in Janis, supra note 121, at 158 n.43.
123. See http://www.ipaustralia.gov.au/patents/what-innovationreview.shtml
(last visited Apr. 12, 2004), at recommendation no. 2, cited in Janis, supra note 121,
at 173 n.122.
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more formal legislation could be passed by Parliament.1 4 Just three
months later in August, the Australia and New Zealand Food Safety
Council decided in principle on mandatory labeling of GM food,
though the cost was estimated at more than $A 2 billion (U.S. $1.5
billion)'25 in only the first year, compelling the council to rethink its
options. 26 In March 2000, a revised report dramatically reduced the
estimated labeling costs to $A 315 million. The report was followed by
a 1,000 hectare-trial of GM cotton in Western Australia; after illegal
GM canola was found dumped in a bin in South Australia in April
2000, however, the West Australian government froze all commercial
releases of GM crops for two years.127
These events precipitated the Australian Patents Amendment Bill
2001 (Cth), 28 which sought to make it easier for individuals to patent
GM products, though it did not take any steps to address directly the
risks. Indeed, the Bill widened the scope of IP publications which
qualified for meeting the "novelty, inventive step, and innovative
step"' 129 requirement for patent protection (i.e., they could be from
anywhere in the world instead of just in Australia) - but not much
else. This arguably harmonized Australia's legislation with other
patent regimes, though on its face it was somewhat superficial. It did
little to address issues stemming from the 1997 amendments which
created a "second tier" patent scheme, which by all accounts was not
working as was hoped. Mark Janis, who wrote extensively about such
schemes in a recent article in the Harvard International Law Journal
noted many problems with such "second tier" schemes, including the
observations that (a) lower application fees bear little relation to
ultimate costs, due to attorney's fees which can comprise fifty percent
124. Food Fight, supra note 44.
125. See http://www.x-rates.com/calculator.html (last visited Apr. 17, 2004)
(providing swift currency calculations on the web and noting an exchange rate of A
$1.31 to US $1).
126. Id.
127. Id.
128. "Cth" refers to Commonwealth (i.e., federal) legislation passed by the
Australian Parliament, as opposed to state and territory legislation passed by one
of Australia's seven states or the Northern Territory [these include - proceeding
clockwise from the northeast - Queensland (Qld), New South Wales (NSW), the
Australian Capital Territory (ACT), Victoria (Vic), Tasmania (Tas), South
Australia (SA), West Australia (WA), and the Northern Territory (NT)].
129. See Patents Amendment Bill, 2001 (Austl.); see also Carolyn Harris,
Patents Amendment Bill, WATERMARK JOURNAL, March, 2002, available at
http://www.watermark.com.au/ (last visited Apr.13, 2004).
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of acquisition costs and later enforcement actions; (b) speed is largely
a misnomer since enforcement actions require judicial review; (c) the
standard for "nontraditional subject matter '"' ° is also a misnomer given
its semblance to the standards for regular patents; and (d) little, if any,
GMC technology comes from smaller, "indigenous" enterprises,
rendering the system largely moot.T3 With secret trials of GMCs
reported in the Australian outback1 32 and the risks of GM pollen
integrating with wild-type strains, 33 IP issues spanned a much broader
scope than the issues addressed by the most recent bill.
Australia's attempts to revamp its IP system thus failed to address
key issues. Nothing in its amendments addressed the argument that
strong IP protection was "necessary to offset the enormous cost of
research" in IP areas,'3 though the technologies were of such a nature
that they seemed like public goods. David Dumaresq, Head of the
Australian National University's Faculty of Science, stated,
"Australians will be giving away intellectual property rights over the
basic building blocks of life if genetic modification is allowed to
continue ... making the mistake scientists of the 1 9 th century did not
make. ' 35 On the other hand, at issue were "basic biological processes"
which often appear to defy private ownership. Kim Woods draws a
parallel between GMCs and basic oxidation processes: it would be
madness to require scientists to pay royalties on basic chemical
processes, she argues, just as it would make little sense to require
royalties to be paid on genetic manipulative processes.136 A prime
example of this is the pPlex technology developed by RhoBio, a joint-
venture between Rhone-Poulenc Agro and Biogemma, in cooperation
• .- x • . • 131
with CSIRO, Australia's National Research Organization. pPlex is
essentially a set of "DNA switches for turning genes on and off,
enabling the expression of genes giving plants new trait[s] such as
130. Janis, supra note 121, at 190-193.
131. Janis, supra note 121, at 184-185.
132. See Laurie, supra note 28.
133. Mary A. Rieger et al., Pollen Mediated Movement of Herbicide Resistance
Between Commercial Canola Fields, 296 SCIENCE 2386-2388 (2002); see also
Exhibits 2-3, contained in the Appendix (highlighting results of the study).
134. Weston, supra note 1, at 380.
135. Kim Woods, 'Debate is Needed' on Genetics, WEEKLY TIMES, Mar. 15,
2000, at 12.
136. Id.
137. Editorial Staff, RhoBio Signs a Plant Biotechnology Research Agreement
with CSIRO in Australia, PR NEWSWIRE, Sept. 28, 1999.
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herbicide tolerance or resistance to insects or disease.,138 In many
ways, however, this is neither unique nor novel because this is a
fundamental process which is present in all genes and applied by
humans who first developed crops thousands of years ago around the
Tigris and Euphrates rivers. 9 A stronger argument can be made for
patenting the research work by teams from Belgium and Australia to
"identify and patent sequences of genes from three strains of banana
streak virus."'40 Because the teams focused on identifying three gene
promoter sequences from the virus which acted to switch on 154 new
genes so the plants exhibited a set of desired characteristics,'' their
'discovery' could be seen as more "novel." In Australia, it is not clear
which of these ostensible inventions would be protected. Furthermore,
a proposed Gene Technology Act does little but create "GM-free
zones" within states to address the fear that Australia would lose key
overseas markets if GMCs got into the supply chain.' 42
III. THE ROLE OF INTELLECTUAL PROPERTY (IP)
A. Power Dynamics, Floating Seeds, and Localizing Fault
As noted above, IP issues are arguably the biggest stumbling block
- and source of potential benefits - of GMCs. IP rights and
guidelines ultimately determine the amount of money a technology
owner can make by allowing the owner to set margins and establish
license fees based on market forces. An IP owner can also influence
where production will occur and dictate the terms of trade. Australia,
in these regards, has been cited as not being "particularly clever at
devising structures in which intellectual property can be protected,
developed and traded" from Australia because it has too often "sold
off rights to publicly funded research at a very early stage for paltry
returns.'1 3 There are issues addressing international trade, which in
138. Id.
139. See generally DIAMOND, supra note 6.
140. Simon Grose, Banana-Gene Therapy Patent Signals Boost in Production,
THE CANBERRA TIMES, Jan. 5, 1999, at A3.
141. Id. The plants included corn, sorghum, canola, millet, grasses, bananas,
sugarcane, trees, ferns, and plant tissue under pressure.
142. See Laurie, supra note 28.
143. Clarke, supra note 24.
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Australia's case are poignant given its small size, and feeling that in
order to "maintain its edge" in world agriculture, it needs to "identify
genes" important for these purposes.144 Finally, there are issues of
where IP rights and responsibilities begin and end; in the case of
GMCs and floating pollen particles, these issues address who should be
held responsible if nature incorporates GMCs into its fold and these
GMCs are unknowingly used by others. A series of additional issues
further deserve mention in these regards, including (a) the current
nature of GMC research and IP owners; (b) the wide array of
individuals affected by GMCs; (c) the subtleties of defining IP rights
for GMCs; (d) the problems of concentrated market power; and (e)
more general policy concerns. They all help "set the stage" and give
one a sense of the broad range of issues surrounding IP rights and
GMCs today. Each of these is considered in turn.
First, it is important to recognize that most biotechnology companies
are small and have tight resources and, thus, little power. 4' The
current IP regime, with or without second tier patenting systems, is
thus deleterious because of the likely risk of litigation over issues
which are neither clear nor clear-cut. The prohibitive costs of
enforcing patent rights has become a major problem, with second tier
patent systems proving inadequate because of their promises of shorter
term protection and less rigorous protection standards.' Indeed, a
second tier patent system cannot solve access problems that may vary
dramatically from place to place (making harmonization across
borders incredibly difficult, if not impossible) and fails to consider
enforcement costs. 147 There is also no doubt that patenting is essential
for researchers in the modern era. A clear example is the "blue gene"
in carnations, which Florigene was able to patent and trademark just
three months before its rival resulting in the famous Moondust
carnationTM en route to developing the elusive blue rose.' 48 If one does
not patent quickly, then one's discovery could be claimed by others.1
49
144. See Liz Dennis, Biological Revolution, HOME Hiss OBSERVER, Jan. 10,
2002, at 9.
145. Weston, supra note 1, at 380 (noting that "[in] 1998, there were 1,283
domestic biotech firms, roughly two-thirds of which employed fewer than 135
persons").
146. See Janis, supra note 121, at 152.
147. Id. at 154.
148. MATP, Patent or Perish, Science Doyen Says - Thinking Melbourne, THE
AUSTRALIAN, Nov. 3, 1998, at 6.
149. An example of this in the case of Trademarks is the image of bell which
had been associated with the collection of companies known as the "Bell system"
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Second, the individuals affected by GMCs now extend well beyond
the individuals who expressly purchased rights or consciously assumed
risks associated with the GMCs, and this poses significantly
challenging legal and philosophical issues with regards to who should
have responsibility for GMCs' unintended consequences. A study of
canola pollen drift in Science on sixty trial fields across South Australia
concluded that unwanted gene transfer only occurred in 0.07 percent
of cases - supporting the conclusion that "non-GM crops" were not
"in any danger."15 On the other hand, as discussed below, seeds have
been found to float and farmers have been held responsible.
Monsanto went to efforts to ensure that it retained property rights for
seeds used by those who purchased them, though it has taken actions
indicating it should have rights to 'floating seeds,' too.' This
underscores the imperative of improving regulatory processes to
''ensure a proper weighing of the full social benefits and costs of
agricultural biotechnology" and to "clarify liability rules governing the
use of agricultural biotechnology. 1 52 There is also the fact that patents
have been used to gauge farmers. A case in point is the gene
protecting cotton from insect attack, which was licensed at $110 per
hectare to U.S. growers and $245 to Australian growers because of
Australia's marginalized position as an exporter. 1-3 In this light, it is
imperative that farmers be clearly accounted for as "integral part[s] of
agricultural biotechnology," especially when property rights are
interpreted. -4
A third main area addresses the way IP statutes and patents are
construed. Does the word "growing," for example, mean "making" or
"using"?'55 If the former, then a host of GMC IP rights flow to the
producers of the seeds and, possibly, the genes, though users can be
insulated from potential IP infringement; contrarily, if the latter,
operating local and long distance telephone services for AT&T before it was
divided. The image, it turned out, had not been copyrighted, so an industrious
employee did so and subsequently demanded millions of dollars in royalty
payments for the image which was ubiquitously prominent throughout the United
States. Interview with Leonard Macaluso, former engineer for AT&T Bell Labs, in
Clifton, NJ (Mar. 12, 2003).
150. Rieger, supra note 133, cited by Laurie, supra note 28.
151. See generally Van Cleve, supra note 50.
152. Id. at 246.
153. MATP, Genes Threaten Bigger Harvest, THE AUSTRALIAN, Nov. 9, 1998, at
5.
154. Busch, supra note 85, at 4.
155. See Busch, supra note 85, at 134.
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individuals unknowingly incorporating IP technology in their own
efforts (as farmers or organic cross-breeders) can be held liable for
using the technology without permission. There are also different
"schools" of thought vis-A-vis assessing patent infringements. The
"American school" focuses only on a final product and testing if it is
equivalent to other patented products, while the "European school," in
contrast, looks at the process taken to achieve a final result, which
absolves all those achieving an already patented result of liability if the
process they follow substantially differs from that taken by the original
patent holders.
As mentioned above, a fourth concern is the ability of large
companies, like Monsanto, to corner the market with their technology.
Monsanto's response to being barred from using its Terminator Seed
technology after its patent for glyphosate expired in September 2002
was to institute Technology Use Agreements (TUAs). These
prevented farmers from giving unused seeds to others or saving seeds
for the next season. They also, however, went beyond the use of the
seeds and included provisions which required growers to only use
Monsanto products on Monsanto GMCs. Monsanto also reserved its
right to enter freely onto farmers' properties and inspect growers'
fields for "seed pirating" whenever it wished."7 One can legitimately
argue that Monsanto was within its rights in securing these guarantees
given its patents. On the other hand, the scope and extent were
unprecedented and were an omen for many farmers of future legal
demands and requisites. In this respect, the "biggest concern" about
GMCs is the "corporate attempts to dominate world markets by
owning the technology.'
158
The fifth area is one of more general social policy, particularly
internationally, with regard to GMCs. Many companies may want to
head to countries with ostensibly strong IP protection, such as
Singapore, 59 but what does this mean if the country's market is
obviously limited? A key area of policy evolution relates to
developing rules that govern biological inventions internationally, fully
addressing their "presumed risks to human health and the
156. See York, supra note 31, at 434-435.
157. Nicole C. Nachtigal, A Modern David and Goliath Farmer v. Monsanto:
Advising a Grower on the Monsanto Technology Agreement, 6 GREAT PLAINS NAT.
RESOURCES J. 50, 59 (2001).
158. Australian Associated Press General News, GM Danger Greatest in
Control of the Technology (Sept. 25, 2002).
159. See Chang Ai-Lien, Pulse Quickens for the Life Sciences Here, STRAITS
TIMES, Nov. 1, 2002.
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environment" worldwide.' 60 Tools for risk management exist, such as
the aforementioned "precautionary principle," though this provides
little protection because it can be applied intermittently and
inconsistently. The concern with coordinating policy addressing living
organisms and GMCs among disparate nations has remained.
Calestous Juma and Victor Konde, for example, make the telling
observation that "historically, living organisms have fallen outside the
scope of protection by most intellectual property systems; now, the
question is whether it falls outside the public interest."'
61
These points culminate in the proposition that it is imperative for
countries like Australia - instead of focusing energies on secondary
patent protection regimes - to "direct[] energies towards the reform
of regular patent law, and towards the exploration of alternative
avenues for protecting incremental innovation. '"1 62 The key question is
how this can best be done.
B. Patentability Issues
The locus of IP protection is patent law, which is the main area
needing revision to accommodate GMCs and their related
technologies. Basic patent protection law is essentially quite simple:
one gets a limited term of protected "exclusivity" to a new invention
(the benefit) by making the discovery completely available and
accessible to the public (the cost). Individuals cannot directly benefit
from the invention because of the exclusive rights granted to the
patent holder. It is hoped that understanding the patent and what it
creates, however, can and will stimulate further research, discoveries,
and inventions. In the United States, the first country to introduce a
formal patent regime, patent laws stem directly from the Constitution.
Article 1 explicitly states that one of Congress' goals is to "promote
the Progress of. . . useful Arts, by securing for limited Times to...
Inventors the exclusive Right to their respective.. . Discoveries."
'' 63
In essence, patentable items must be novel and useful and "non-
obvious"; 164 in Australia, similar to many other developing nations,
these concepts are captured in the statutorily specified needs for
160. Calestous Juma & Victor Konde, Industrial Applications for Biotechnology:
Opportunities for Developing Countries, 44 ENVIRONMENT 2235 (2002).
161. Id.
162. Janis, supra note 121, at 219.
163. U.S. CONST. art. 1, § 8, cl. 8.
164. See 35 U.S.C. §§ 102-103 (2000).
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"novelty, '1 65 an "inventive step,"'66 and an "innovative step.' ' 167
Novelty is required as a barrier from preventing technology from being
patented which is already in the public domain; utility, at least in the
United States, ensures that the government only gets involved if the
public is expected to derive benefits; and non-obviousness (or
inventiveness) is necessary to prevent granting rights to individuals for
taking actions which would be apparent to one skilled in the relevant
field.' 68 These rights vest when the object takes physical form' 69 and
are largely rooted in the old-fashioned ideas of inventors making new
objects in backyard barns, such as the prodigious John Yates.171
The theoretical underpinnings of patent law stem from many
sources. Foremost are fundamental principles of property which,
generally speaking, recognize human "dominion over a thing
reinforced by the power of exclusion.'' 7 Foremost in bringing such
"dominion" to fruition is the idea of "first occupancy"- namely, the
fact that he who stakes the first claim on something takes the thing.
This concept was the basis of the European settlement of Australia,
which viewed the land as terra nullius (literally: land belonging toS 172
nobody), albeit this concept was debunked by the High Court's
recognition of Native Title in the famous Mabo case.'73 The second
major underpinning of dominion is Locke's concept of "labor-
165. See Patents Act, 1990, § 7(1) (Austl.).
166. Id. at § 7(2).
167. Id. at § 7(4)-(6). See generally GOLVAN, supra note 120.
168. See generally LI WESTERLUND, BIOTECH PATENTS: EQUIVALENCE AND
EXCLUSIONS UNDER EUROPEAN AND U.S. PATENT LAW (2002); Toshiko Takenaka,
Comparative Study of Patent Claim Interpretation in the United States, Federal
Republic of Germany, and Japan (1992) (unpublished Ph.D. Thesis, University of
Washington) (on file with the author).
169. See Busch, supra note 85, at 52.
170. Yates is best known for inventing the speed-loader bag technology which
put loaves of bread into plastic bags, though is also known for an array of other
inventions. Yates is known to have said that "inventing is a hard slog. Paranoia is
essential." Editorial Staff, Ideas People, NEWCASTLE HERALD, Oct. 10, 1998, at 48;
see also Editorial Staff, Inventor Who Touches Us All, NEWCASTLE HERALD, Sept.
30, 1998, at 39.
171. See Yelpaala, supra note 2, at 124.
172. See Carlos Scott L6pez, Reformulating Native Title in Mabo's Wake:
Aboriginal Sovereignty and Reconciliation in Post-Centenary Australia, 11 TULSA J.
COMP. & INT'L LAW 21, 22 (2003).
173. See Mabo v. Queensland [No 1] (1989) 166 CLR 186; Mabo v. Queensland
[No. 2] (1992) 175 CLR 1.
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insertion"- namely, that "a person is entitled to the fruit of his
labor,' 74 but not all products of one's labor constitute property (e.g.,
one's child) and not all property is the product of one's labor (e.g.,
one's internal organs). 75 The patent, then, is an attempt to elucidate
one's "dominion" over certain ideas in a quid pro quo statutory
bargain whereby the patentee gets a monopoly while giving the public
knowledge it would not have otherwise obtained.'76 Patents are thus a
"law of secrecy supported by the law of contract" capturing elements
of both branches of law. 77  As such, one must ask whether this
exclusion makes sense for GMCs and, if not, how it should be changed.
Independent of the philosophical arguments that nothing which is
"naturally occurring" and is a "public good" should be owned, there is
the fact that GMCs and genetic alterations also often lack specificity
and inherent uniqueness. Copying genes is not like copying computer
disks: it is a quasi-binary system, with the replication process (through
RNA) neither necessarily exact nor secure. Variation and mutation is
the essence of genetic development and genetic analysis; thus, even the
best "inventions" can be changed by nature itself.
7 1
The locus of this problem stems from the fact that property is of
three types and it is not clear which type GMCs are or should be. The
first type, on which IP patent regimes are currently based, assume that
GMCs are private property having (a) identifiable owners with (b) all
or most of a core bundle of rights. The second type, in contrast,
applies to commons property in which no individual holds a right to
exclude others so multiple individuals can enjoy the privilege of using
the property; this is most often applied to natural resources such as air
and light. The third type, to which GMC technologies might belong, is
anticommons property in which multiple users have the right to
exclude others from a resource over which they disagree who should
have access; this then ensures that nobody has the effective privilege of
using or accessing the resource. The law recognizes, in the case of
private property, the use of easements to ensure individuals' rights to
certain property; with anticommons property, however, easements are
impossible because of the de facto inalienable private property rights
which contribute to the anticommons. In the case of GMCs, which
174. See Yelpaala, supra note 2, at 160.
175. See id. at 133-4.
176. See Monsanto Canada, Inc., v. Schmeiser, [2002] FCA 309, at 30.
177. See Yelpaala, supra note 2.
178. Essentially, mutations are induced in GMCs to create the desired results.
See Exhibit 4, contained in the Appendix, listing the methods used to induce
mutations in developing a range of major GMCs.
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often rely on technologies and "upstream" research requiring sets of
pieces to be assembled - all owned by different individuals -
"concurrent fragment '1 79 anticommons property results (i.e., a series of
protected pieces which either cannot be assembled without cross-
licensing agreements or, in the case of Monsanto, are owned entirely
by Monsanto which controls all access rights). The pre-clinical
discovery phase of drugs illustrates this well, with the segments of (a)
gene sequencing, (b) gene hunting, (c) gene functioning, (d) drug
target identification, and (e) validation all needed to make a successful
drug; none can be overlooked or avoided.' 8  Similarly, genetic
information resists control because it exists within every living being
and "will continue" to do so "regardless of the institutions created to
deal with the legal repercussions of its manipulation. 1 1 GMCs thus
appear to be quintessential commons property, with anticommons
repercussions.
For these reasons, GMCs and other genetic inventions "initially
struggled to overcome the utility barrier to patentability,"""n with lower
standards drawing opposition because of their tendency to recognize
IP rights to property whose functions were unknown. Cases in point
are gene sequences, for which individuals could theoretically gain
patents even when others discovered what the sequences actually did.
83
In these regards, problems emerged about the written description
requirement and ensuring that descriptions were full and complete.
One of the first seminal cases addressing this matter was Regents of the
University of California ("UC") v. Eli Lilly,84 in which UC sought to
prove infringement of a patent 85 which it had obtained for identifying
DNA sequences comprising vertebrate insulin-encoding regions and
bacterial expression vectors containing the sequences. Eli Lilly had
used a bacterial system to produce a type of human insulin after
attaching a length of bacterial protein; the bacterial protein portion
was then subjected to a cleavage step from which active human insulin
179. Janis, supra note 121, at 202.
180. See Gene Genie, supra note 107.
181. Alexis Gorton, Edible Equivalents: An Increase in Patent Protection for
Genetically Modified Organisms, 9 WASH. U. J. L. & POL'Y 321, 326 (2002).
182. See Weston, supra note 1, at 388.
183. See id.
184. Regents of the University of California ("UC") v. Eli Lilly, 119 F.3d 1559
(Fed. Cir. 1997).
185. Patent no. 4,652,525 was at issue in the case. See Regents, 119 F.3d at 1569.
[Vol. 20:367
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emerged.' The UC patent was ultimately deemed invalid because it
failed to describe its invention adequately in writing.
87
Another major challenge posed by GMCs and genetic inventions is
the genetic code's degeneracy, and the fact the code can change
dramatically over time."" Given the fact that each amino acid can be
described by a range of different codons, 89 the question arises as to
how specific one can or should be required to be in patenting a
sequence. The effect of a small modification of an amino acid in a
protein (e.g., by the substitution of one amino acid for another) can
have either minimal or dramatic effects.'9 Whether or not a
substitution alters the backbone of a given protein, destabilizes the
hydrophobic core, results in significant steric clashes, or destabilizes
key hydrogen bonds all contribute to determining if the change is
significant. Despite the advancement of science, it is still impossible
to predict a protein's exact structure simply given its amino acid
sequence. However, key patterns and trends have been identified.' 9'
This has led academicians such as Kojo Yelpaala to propose that there
are three levels of patentability for modern genetic innovations.' 92 The
first are those discoveries which have been simply outlawed because
they offend moral sensibilities, independent of specificity; human
cloning and creating new stem cell lines fall in this area. Second are
items which are subjected to more serious scrutiny, such as gene-
therapy, organ cloning, and developing new seed, plant, and animal
varieties, largely hinging on whether scientists are creating anything
186. Weston, supra note 1, at 391.
187. Regents, 119 F.3d at 1569, cited in Weston, supra note 1, at 391 n.116.
188. See generally GENETIC ANALYSIS, supra note 49; JEREMY M. BERG, JOHN
L. TYMOCZKO & LUBERT STRYER, BIOCHEMISTY (5"' ed. 2002); WILLIAM K.
PURVES ET AL., LIFE: THE SCIENCE OF BIOLOGY (6th ed. 2001).
189. See infra Exhibit 8, summarizing the codon sequences coding amino acids.
190. See infra Exhibit 7, for examples of some dramatic effects.
191. See generally David Baker & Wendell Lim, Folding and Binding: From
Folding towards Function, 12 CURRENT OPINION IN STRUCTURAL BIOLOGY 11-13
(2002); BERNARD GLICK & JACK PASTERNAK, MOLECULAR BIOTECHNOLOGY
(1998); Wendell Lim & Robert Sauer, Alternative Packing Arrangements in the
Hydrophobic Core of Lambda Repressor, 339 NATURE 31 (1989); Wendell Lim &
Robert Sauer, The role of Internal Packing Interactions in Determining the
Structure and Stability of a Protein, 219 J. MOLECULAR BIOLOGY 359-376 (1991);
Jay Ponder & Frederic Richards, Tertiary Templates for Proteins: Use of Packing
Criteria in the Enumeration of Allowed Sequences for Different Structural Classes,
193 J. MOLECULAR BIOLOGY 775-791 (1987); Frederic Richards, The Protein
Folding Problem, Sci. AM., Jan. 1991, at 54-63.
192. See Yelpaala, supra note 2.
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new or instead just doing what nature has already taught humans how
to do (albeit more indirectly in the past). Finally, there are those
items which appear to pose no threat to the "natural order" of things
and should be simply specified as much as possible; identifying a
means of mass producing a theoretical, naturally growing herb used by
a group of indigenous people to address a simple malady would most
likely fall into this category. 93
Responses to these issues have taken many forms. The United
States passed the first patent law protecting breeds of asexually
reproducing plants in 1930, M though not until 1970 did it protect
sexually reproducing plants.9  Utility patents for other living
organisms were only recognized in the seminal U.S. Supreme Court
case Diamond v. Chakrabarty,'96 upheld in J.E.M. Ag. Supply, Inc. v.
Pioneer HOBred Intern, Inc.'97 In Diamond, Chief Justice Burger,
writing for a divided 5-4 court, held that the language of section 101 of
the Patent Act was broad enough to cover the patents of genetically
engineered bacterium and microorganisms. 198 Justice Brennan, writing
for the four dissenters, however, noted that despite the broad language
of the Patent Act, Congress anticipated the need to address special
biological inventions separately, as evidenced by the separate Plant
Patent Act and Variety Protection Acts.' 99 He further held that these
acts "strongly evidence a congressional limitation that excludes
bacteria from patentability."2°° Four special criteria for protecting
plant products are noted in 7 U.S.C. § 2402, 201 buttressing Brennan's
193. See Yelpaala, supra note 2. See also infra Exhibit 13, illustrating
figuratively a way of thinking about items which should and could be patented.
194. See Plant Patent Act 1930, 35 U.S.C. § 163 (2002).
195. See Plant Variety Protection Act 1970, 7 U.S.C. § 2321 (2002), cited in Kim,
supra note 89, at 1160 n.115
196. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
197. J.E.M Ag. Supply, Inc. v. Pioneer HOBred Intern, Inc., 535 U.S. 1013
(2001).
198. Diamond, 447 U.S. at 305.
199. Id. at 319; see also Klaus Bosselmann, Focus: Plants and Politics: The
International Legal Regime Concerning Biotechnology and Diversity, 7 COLO. J.
INT'L ENVTL. L. & POL'Y 111 (1996).
200. Diamond, 447 U.S. at 319.
201. 7 U.S.C.A. § 2402 states:
§ 2402. Right to plant variety protection; plant varieties protectable
(a) In general
The breeder of any sexually reproduced or tuber propagated plant
variety (other than fungi or bacteria) who has so reproduced the variety,
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claims. Five years later, the Board of Patent Appeals faced the
question of whether seeds were patentable as living organisms like
bacteria and microbes under Diamond. In Ex parte Hibberd,2°  the
United States Board of Patent Appeals and Inferences (BPAI) held
that plant matter can be patented following the rationales in Diamond
because § 101 included, according to the Supreme Court in Diamond,
"everything under the sun made by man" 203 and that the plant matter
thus met the "statutory requirements for a utility patent."
24
Silence was the rule in the U.S. until 1999, when a Delaware court
debunked the value of scientific processes in Monsanto Co. v. Mycogen
Plant Science, Inc.205 In Mycogen, the Court held that two U.S. patents
held by the Mycogen Corporation covering Bacillus thuringiensis (Bt)
gene technology used to make insect-resistant plants were invalid
because of the processes used to make the plants (which were
genetically identical to two species already patented by Monsanto).2
The Court focused its analysis on the production process of a modified
chimeric gene (MCG) which could be made in two ways. The first,
known as "site-directed mutagenesis," was originally used by
or the successor in interest of the breeder, shall be entitled to plant variety
protection for the variety, subject to the conditions and requirements of
this chapter, if the variety is-
(1) new, in the sense that, on the date of filing of the application for
plant variety protection, propagating or harvested material of the variety
has not been sold or otherwise disposed of to other persons, by or with the
consent of the breeder, or the successor in interest of the breeder, for
purposes of exploitation of the variety....
(2) distinct, in the sense that the variety is clearly distinguishable from
any other variety the existence of which is publicly known or a matter of
common knowledge at the time of the filing of the application;
(3) uniform, in the sense that any variations are describable, predictable,
and commercially acceptable; and
(4) stable, in the sense that the variety, when reproduced, will remain
unchanged with regard to the essential and distinctive characteristics of
the variety with a reasonable degree of reliability commensurate with that
of varieties of the same category in which the same breeding method is
employed.
202. Ex Parte Hibberd, 227 U.S.P.Q. 443 (Bd. Pat. App. & Infer. 1985).
203. Diamond, 447 U.S. at 309.
204. Nachtigal, supra note 157, at 56 n.51 (referencing Ex parte Hibberd, 227
U.S.P.Q. 443,447 (Bd. Pat. App. & Infer. 1985)).
205. Monsanto Co. V. Mycogen Plant Science, Inc., 61 F. Supp. 2d 133, 143 (D.
Del. 1999).
206. Id.
2004]
Journal of Contemporary Health Law and Policy [Vol. 20:367
Monsanto. This process involved designing a gene by substituting one
or more nucleotides at predetermined sites in a natural gene. 2°7 The
second, termed "chemical synthesis" and developed by Mycogen,
involved creating synthetic DNA by chemically linking nucleotides in
the proper sequence to produce the desired DNA sequence and then
incorporating the synthetic DNA into the native gene to alter the
sequence of that native gene.2 8 The defendant, Mycogen, argued that
a MCG included only those genes made by site-directed mutagenesis
- which it did not perform - while Monsanto argued that a MCG
could be made by either method and its patent for the gene in question
essentially covered all means used to make it.2°9 The Court ultimately
ruled in Monsanto's favor, establishing a precedent that Mycogen's
chemical synthesis method, while novel, broke Monsanto's patent and
Monsanto deserved compensation. Notably, this result comported
with common law standards that "inventive steps" were
inconsequential to an invention (i.e., the process leading to a result)
and only the "novelty" mattered (i.e., the result itself). This
dramatically increased Monsanto's power, and had important
implications for biotechnology IP rights.
Globally, these issues have found parallels in key international
agreements, though few countries have faced judicial controversies
similar to those in the U.S. by virtue of the amount of IP in the U.S.
The Convention for the Protection of New Varieties of Plants (UPOV)
in 1961,211 for example, dealt with breeders' rights instead of patents,
holding that IP protection for new plant varieties would only be upheld
if the new varieties were (a) distinguishable based on one or more key
characteristics, (b) sufficiently homogenous in their sexual
reproduction or asexual propagation, and (c) stable in their essential
212characteristics. The General Agreement on Tariffs and Trade
207. See generally Michael P. Weiner et al., Site-Directed Mutagenesis Using
PCR, in MOLECULAR BIOLOGY: CURRENT INNOVATIONS AND FUTURE TRENDS
(A.M. Griffin and H.G. Griffin eds., 1995).
208. Monsanto, 61 F. Supp.2d at 143.
209. See id. at 144.
210. Id. at 150.
211. International Convention for the Protection of New Varieties of Plants of
Dec. 2, 1961 [UPOV], as revised Nov. 10, 1972, Oct. 23, 1978, and Mar. 19, 1991
available at http://www.austlii.edu.au/au/other/dfat/treaties/2000/6.html (last
visited Apr. 14, 2004).
212. See Kim, supra note 89, at 1160-61 n.120. UPOV also had a "saved seed
exemption" allowing farmers explicitly to save seed for future growing seasons or
sell "saved seed" to other growers. Nachtigal, supra note 157, at 54 n.38. Congress
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(GATT) took up this mantle in the annexed Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) by ensuring
that IP patent protection was available for any inventions, whether
products or processes, in all fields of technology, provided that they
are new, involve an inventive step, and are capable of industrial
application. 3 Most notably, however, TRIPS also included a notable
exception to patentability where any inventions could be excluded in
the interests of protecting "human, animal, or plant life or health or...
avoid[ing] serious prejudice to the environment. ' '21 4 In this light, critics
have found TRIPS disquieting 5 as it has opened up potential
floodgates of disagreements over what things should and should not be
patentable. In the Uruguay round, arguments over the scope of patent
protections (i.e., developing countries had and wanted shorter IP
patent protection times) and ways to accommodate piracy and the
local use of foreign trademarks went unresolved.2 6
The status of IP patent claims thus vary enormously in different
jurisdictions, though there are two particularly challenging trends
which deserve mention. First, it is now clear that one can overturn a
patent by arguing that patent holders have failed to pursue rigorous
experimentation to confirm all possible mutative arrangements of a
genetically modified product. At issue here are the claims of patent
holders which "circumscrib[e] the technology protected by the
patent.",217 An excellent case study from the United States illustrating
this principle is Amgen, Inc. v. Hoechst Marion Roussel Inc.,218 which
addressed the IP rights of the recombinant form of erythropoietin. In
Amgen, Hoechst and Transkaryotic Therapies (TKT) defended their
eliminated this in 1994 and the Supreme Court limited a "saved seed" exemption
which remained in Asgrow Seed Co. v. Winterboer, 513 U.S. 179 (1995) (holding
that a "grower is prohibited from selling seed to other farmers in excess of the
amount needed to grow on his own farm"), cited in Nachtigal, supra note 157, at 55
n.42.
213. Final Act Embodying the Results of the Uruguay Round of Multilateral
Trade Negotiations, Apr. 15, 1994, Legal Instruments-Results of the Uruguay
Round, vol. 1, 33 I.L.M. 1125 (1994), Annex 1C, Agreement on Trade-Related
Aspects of Intellectual Property Rights, 33 I.L.M. 1197 (entered into force Jan. 1,
1995) [hereinafter "TRIPS"].
214. TRIPS, supra note 213, at 1208 art. 27(2).
215. See Pepa, supra note 27, at 417.
216. See id.
217. Weston, supra note 1, at 393 n.133, citing 35 U.S.C. § 112 (1994).
218. Amgen, Inc. v. Hoechst Marion Roussel, Inc., 3 F. Supp. 2d 104 (D. Mass.
1998).
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production of the protein in human cells because these cells produced
a fully human protein in which carbohydrate groups were attached in
the cells.219 This contrasted with Amgen's process, which used
hamsters in which, as expected, hamster-specific carbohydrate groups
were attached. The Court held that Hoechst and TKT's action fell
within a "limited clinical trials exemption from patent infringement, 20
and paved the way for more opaqueness in guaranteeing inventors the
IP rights to their discoveries. How to strike a balance between
ensuring that patents are broad enough to ensure benefits - yet not
too narrow so they are open to litigation and struck down - is the
ultimate balancing test which needs to be made.
A second major challenge is meeting the standards of "the doctrine
of equivalents" (TDOE) referenced earlier. In essence, TDOE is a
legal means to protect patent holders from "small changes" in their
inventions when these are used by others. TDOE thus holds that
"infringement exists when all elements of [an] invention are
substantially equivalent to the elements of the accused device such that
one skilled in the art would know of their interchangeability.",221 The
"same-function-way-result (SFWR) test," first enumerated by the
Supreme Court of the United States in Graver Tank & Mfg. Co. v.
Linde Air Prods. Co., 222 captures the essence of TDOE. In Graver, the
Court held that "[t]o prohibit [only literal infringement] would place
the inventor at the mercy of verbalism. ' '223 At issue in the case was
Graver's patented welding flux composition containing alkaline earth
metal silicates calcium and magnesium, which appeared strikingly
similar to Linde's flux composition containing calcium and224
manganese. Graver Tank prevailed, with Justice Jackson noting on
behalf of the Court that "to permit imitation of a patented invention
which does not copy every literal detail would be to convert the
protection of the patent grant into a hollow and useless thing., 225 The
advent of GMCs calls TDOE into question given the fact that GMCs
exhibit variations which, ceteris paribus, would fail the SFWR test.
219. See id. at 105.
220. Id. at 104.
221. Gorton, supra note 181, at 336. Invocation of TDOE typically results in
both a permanent injunction preventing the patent infringer from continuing his
activity and extensive damages to put the patent holder back "in the position she
would have been in had the infringement never taken place." Id. at 338.
222. Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950).
223. Id. at 607, cited in Weston, supra note 1, at 397 n.155.
224. Graver Tank, 339 U.S. at 610-11.
225. Id. at 607, cited in Weston, supra note 1, at 398.
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Studies of Monsanto's Roundup Ready' Soybeans, for example,
indicated that they exhibited a significant reduction in two out of three
major phytoestrogens found in soybeans of equivalent species without
Monsanto's genetic modifications and, impliedly, potentially other
soybean varieties with other genetic modifications. This suggests that
Monsanto's patent could easily be invalidated, though time will tell.
Indeed, one approach would assess any new technologies element-by-
element, looking to see if any steps were taken which suggested
infringement; another would look at the whole, attempting to assess
the overall import of the ostensibly new invention. The U.S. Supreme
Court upheld the former approach in Warner-Jenkinson Co. v. Hilton
Davis Chemical Co., 227 though it could distinguish future cases.
Applying IP doctrines to GMCs and biotechnology is rife with
challenges. DNA sequences lack discrete elements, save for the
nucleotides which comprise them. If one is analyzing a GMC,
therefore, then it is virtually impossible for a patent to identify all the
possible genetic sequences which could cause a plant to act in a certain
way or fulfill certain expectations. The number of possible nucleotide
changes could be massive - since other sequences could obtain the
same result - not to mention deleted sequences. Also, the degree to
which one could patent knock-outs poses a special challenge because
one would be seeking to patent something which does not exist; this is
particularly problematic when one considers the fact that DNA can be
knocked out naturally (and regularly) in mitotic events. Furthermore,
there is the fact that huge amounts of DNA are conserved between
species, raising the question of whether a corporation can reserve its
right to conserved genetic information across different species -
including humans - over the entire planet. Clearly, these questions
have no easy answers; they do underscore, however, why the clarion
call for reforming IP rights is ubiquitous and seemingly unending.
Christian Dambrini writes that "globalization of economies cannot be
effective without a strong, affordable, enforceable intellectual property
rights system to protect its results,"' 28 echoing Joseph Villela's
assertions how important it is "that all countries set high standards of
intellectual property protection and enforcement in their national laws
226. Lappe, supra note 95, at 39.
227. Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 516 U.S. 1145 (1996).
228. Christian Dambrini, Globalization of Research and Development: A
Business Viewpoint in Facilitating International Technology Cooperation
Proceedings of the Seoul Conference DSTI/STP/TIP (97) 14/FINAL, Mar. 28, 1999,
at 27, available at www.oecd.org (last visited Apr. 15, 2004) [hereinafter
"Viewpoint"], cited in Souza, supra note 32, at 133 n.16.
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and effectively support and enforce the standards once the improved
laws are in place., 2 9 This is one of many next steps.
C. Lessons from Monsanto Canada
Probably the most seminal case to date addressing a host of these
problems is Monsanto Canada, Inc., v. Schmeiser,230 decided last year in
the Canadian Federal Court. While the case is not international
precedent, its legal analysis is likely to be used by other courts in other
jurisdictions to set precedents in the area of GMC IP property rights.
Unlike other areas of the common law which are often domestically
insulated, IP legal issues have transcended international borders. This
makes sense given the extent to which IP-related activities, particularly
vis-A-vis GMCs, cross borders. Monsanto Canada thus provides a
troubling precedent.
Some background to Monsanto Canada is needed to understand the
import of its holding. For over ten years, Monsanto had become a
leading producer of herbicides, largely a result of its Roundup Ready
TM
herbicide technology.3' Soon before its patent expired, however,
Monsanto began marketing a Roundup ReadyTm seed which was more
enduring, longer lasting, and naturally resistant to bugs. It also, most
notably, contained a gene making plants resistant to Roundup Ready TM
herbicide. 232  By cross-selling the seeds to its Roundup Ready TM
customers in advance of the expiry of its herbicide patent, Monsanto
ensured that individuals making Roundup herbicide off its old patent
would fail to gain any customers to whom it had sold its new Roundup
ReadyTM seed. In a very short time, Monsanto was able to sell huge
numbers of Roundup ReadyTM  seeds, making them arguably
ubiquitous across swaths of Canada.
At issue in Monsanto Canada was whether Percy Schmeiser, a local
farmer, had infringed Monsanto's patent for Roundup ReadyTM seeds
by planting a crop of glyphosate resistant canola having a gene which
was the subject of Monsanto's patent. Schmeiser argued that he had
229. Joseph Villela, Intellectual Property Protection: A Business Viewpoint in
Facilitating International Technology Co-Operation Proceedings of the Seoul
Conference, DSTI/STP/TIP (97) 14/FINAL, Mar. 29, 1999, at 83, cited in Souza,
supra note 32, at 134, n.17.
230. Monsanto Canada, Inc., v. Schmeiser, [20021 F.C. 309.
231. See http://www.monsanto.ca/products/roundupready/index.shtml (last
visited Apr. 13, 2004).
232. See Carpenter, supra note 35.
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no intent and no idea that some of his crops had the gene. In fact, only
trace amounts of plants with the gene of interest had even been
identified. Monsanto's patent, specifically, was for a "genetic insert
which, when introduced into the DNA of canola cells by a
transformation vector, produces a variety of canola with a high level of
resistance to glyphosate. '  In essence, this involved a cloning vector
233. Monsanto Canada, Inc., v. Schmeiser, [2002] FCA 309, at 8. Specifically,
the patent identified the gene of interest as:
1. A chimeric plant gene which comprises
(a) a promoter sequence which functions in plant cells;
(b) a coding sequence which causes the production of RNA,
encoding a chloroplast transit peptide/5- enolpyruvylshikimate-3-
phosphate synthase (EPSPS) fusion polypeptide, which chloroplast
transit peptide permits the fusion polypeptide to be imported into a
chloroplast of a plant cell; and
(c) a 3' non-translated region which encodes a polyadenylation
signal which functions in plant cells to cause the addition of
polyadenylate nucleotides to the 3' end of the RNA;
the promoter being heterologous with respect to the coding
sequence and adapted to cause sufficient expression of the fusion
polypeptide to enhance the glyphosate resistance of a plant cell
transformed with the gene.
2. A chimeric gene of Claim 1 in which the promoter sequence is a
plant virus promoter sequence.
5. A chimeric gene of Claim 1 in which the coding sequence encodes
a mutant 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).
6. A chimeric gene of Claim 1 in which the EPSPS coding sequence
encodes an EPSPS from an organism selected from the group
consisting of bacteria, fungi and plants.
7. A chimeric gene of Claim 1 in which the chloroplast transit
peptide is from a plant EPSPS gene ....
22. A glyphosate-resistant plant cell comprising a chimeric plant
gene of Claim 1.
23. A glyphosate-resistant plant cell of Claim 22 in which the
promoter sequence is a plant virus promoter sequence.
26. A glyphosate-resistant plant cell of Claim 22 in which the coding
sequence encodes a mutant 5-enolpyruvylshikimate-3-phosphate
synthase.
27. A glyphosate-resistant plant cell of Claim 22 in which the coding
sequence encodes an EPSPS from an organism selected from the
group consisting of bacteria, fungi and plants.
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comprising a gene which encoded the 5-enolpyruvylshikimate-3-
phospate synthase (EPSPS) polypeptide. When expressed in a plant
cells, EPSPS allows chloroplast transit peptides to transport it (or an
enzymatically active portion thereof) from the cytoplasm of the plant
cell into a chloroplast. This process ultimately "confers a substantial
degree of glyphosate resistance upon the plant cell and plants
regenerated therefrom."2m  Because the Glyphosate inhibited an
enzyme required to produce a particular amino acid essential for the
growth and survival of a broad range of plants, plants sprayed with a
glyphosate based herbicide, such as Roundup ReadyTM herbicide,
would not survive. A canola plant grown from seed containing the
modified gene, however, would be composed of cells with the modified
gene and would survive if sprayed with a glyphosate-based herbicide.
Monsanto won the case, though the court's reasons pose significant
concern. First, the court held that the property rights granted by the
patent were so clear that - independent of whether Schmeiser did not
intend to use the seed or even if the seed had naturally mutated -
Monsanto's rights to the gene had been recognized by law. Second,
there was evidence that Schmeiser had saved some seeds which were
plant resistant and had thus been duplicitous with regard to the seed.
Third, the court found that reasonable efforts had been taken to avoid
the spread of seeds from other neighbors, but it was not incumbent on
Monsanto to do more than was reasonably necessary to prevent the
inadvertent spread of its seeds by individuals who purchased them.
The implications of the court's analysis were significant. First and
foremost, it suggested that individuals could be held liable for
innocently growing or helping reproduce GMCs. Second, these GMCs
- even if resulting from natural, random mutations - would still be
covered by the IP rights of whoever patented them. Even the
unconscious production 235 of GMCs with patented genes would be
28. A glyphosate-resistant plant cell of Claim 22 in which the
chloroplast transit peptide is from a plant EPSPS gene.
45. A glyphosate-resistant oil seed rape cell of Claim 22.
Monsanto Canada, at 38.
234. See Monsanto Canada, at 42. Monsanto, notably, had been hurting
financially, with its stock tumbling because it could not "deliver" on many
promises; it was just under threat to ensure that its new technologies worked and
worked well. Rachel Melcer, Monsanto Wants to Sow a Genetically Modified
Future, ST. Louis POST-DISPATCH, Feb. 23, 2003, at El.
235. See JAMES LAHORE, INTELLECTUAL PROPERTY LAW IN AUSTRALIA 110,
at 7 (1977).
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tortious activity demanding a cause of action for damages. One of the
reasons why these conclusions are so onerous is their import: because
GMCs are patented inventions which can reproduce, produce progeny,
and travel without human intervention, they are essentially
inescapable. Furthermore, GMCs are also, theoretically, reproducible
unknowingly through the process of random genetic mutations. GMCs
run the risk of completely redefining a host of legal concepts, such as
inventiveness, individual autonomy, and tortious interference. Based
on Monsanto Canada, Monsanto gained an unprecedented set of
legally enforceable rights based on its patent. These include cause to
enter on to private property and even confiscate that property without
the owners' consent, based purely on a genetic sequence which could
occur naturally.
D. International Concerns
Little has been done to address these concerns, and little is likely to
be done. The WTO's TRIPS agreement, mentioned above, may have
"globalized" traditional IP concepts, though has done nothing to assess
the complexities of GMCs vis-A-vis individuals qua companies,
companies qua countries, and different legal IP regimes in different
countries.236 Similarly, the Cartagena Protocol on Biosafety - devoted
to regulations affecting GMCs - does not impose a consistent labeling
scheme for GMCs, though it does require labels for shipments of all
food products, even if they have been shown to prove no risk
whatsoever.37  Biotechnological developments have appeared to
become simply "technical extension[s] of traditional agricultural
selective breeding practices",238 which are both time-tested and "largely
harmless or self-correcting., 239 Depending on the degree to which
other countries agree with this approach, GMCs run the risk of being
given increasingly disparate treatment to the chagrin of those seeking
greater controls. Floating seeds have no borders.
236. See Fredrick Musungu, The TRIPS Agreement, the Patents Controversy and
the Right to Health: Placing the International and National Debates in Context,
unpublished manuscript, Abstract at 1 (2002) (on file with the author).
237. See Michael P. Healy, Information Based Regulation and International
Trade in Genetically Modified Agricultural Products: An Evaluation of the
Cartagena Protocol on Biosafety, 9 WASH. U. J. L. & POL'Y 205, 205-206 (2002).
238. Van Cleve, supra note 50, at 248.
239. Id. at 249.
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There is, however, some hope in the international arena. The
Cartagena Protocol, while imperfect, empowers countries to refuse
to import GMCs under the precautionary principle (i.e., the country
can ban the import even if there is a lack of scientific certainty that
something is dangerous). The Protocol also elevates environmental
considerations to an unprecedented level, lauded by many
environmentalists. The 1961 Union for the Protection of New
Varieties (UPOV) similarly has increased its membership and helped
ensure steps be taken to protect indigenous plants and foods.24
Depending on the degree to which GMCs are found to threaten
indigenous varieties, this agreement could be used in limiting GMCs
posing quantifiable risks.
Still, these initiatives only begin to address the broader set of issues
which remain, including (a) "equitable concerns regarding the
patenting of genetically modified products; '2 42 (b) the level of
transparency for exports of genetically modified products; (c) import
bans on genetically modified products; (d) liability for damage of
genetically modified products; (e) liability for extraterritorial damage
of genetically modified products; and (f) "long-term decline in global
biological diversity. 2 43 The Biosafety Protocol negotiations broke
down in 1999 over issues surrounding whether producers of GMCs had
to obtain explicit permission from importing countries to proceed with
their exports; tentative arrangements were subsequently negotiated,
though the issue has not vanished .2
Hopeful international solutions must be built on a commitment to
address these issues, as embraced in the principles underpinning the
WTO. The WTO, despite its critics' fears, can work to achieve
agreements which have met the needs of rich and poor countries alike.
Its schemes have ostensibly been supported by the principles of (a)
non-discrimination, as encapsulated under the Most Favored Nation
(MFN) status, (b) national recognition, and (c) consistent elimination
of quotas and non-tariff barriers.2 45 The clear need for international
regulation of GMCs and the IP regimes which support them may thus
240. Cartagena Protocol on Biosafety to the Convention of Biological Diversity,
Jan. 29, 2000, 39 I.L.M. 1027 (2000), cited in Healy, supra note 196, at n.2, at
http://www.bba.de/gentech/cartagena.pdf (last visited Apr. 18, 2004).
241. See Nachtigal, supra note 157, at 53-54 n.23.
242. See Sean D. Murphy, Biotchnology and International Law, 42 HARV. INT'L
L. J. 47, 61 (2001).
243. Id.
244. See Kupchella, supra note 101, at 744 nn.193-195.
245. See Souza, supra note 32, at 167.
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be redressed given increasing safety concerns and the interest in
ensuring stability in international trade .2
Indeed, it is possible to allay the fears associated with the
international community's addressing of GMC IP issues. Although
trade representatives have stressed how "it would be a tragedy and
health setback if the promotion of the flexibilities within the TRIP
accord degraded into an assault, 247 on IP, this need not be so.
Effective protection of IP is "critical for developing nations" because
of their need to "find and develop" ways to deal with the public health
challenges faced by their respective societies.24 This opens the door to
considering "utility-based"' 249 standards for IP protection, as opposed to
novelty or originality standards, in the interests of meeting these
needs. Such standards could account for the risks associated with
GMCs and mete out IP rights accordingly.
E. Hopeful Resolutions: Five Guiding Principles
It is impossible to design an optimal IP system accommodating
GMCs in a vacuum. However, the previous discussion of Monsanto
Canada and international developments suggest a set of five key
guiding principles. By embracing these principles, actors such as
NGOs, government representatives, and private citizens could begin
developing new IP systems accommodating GMCs.
Principle 1: IP protection of GMCs must include multiple sets of
rights. The first guiding principle is that IP protection for GMCs needs
to acknowledge the rights of more than just the developers and
manufacturers of the GMCs. To date, all IP systems focus simply on
the developers and ensuring that "patent protection" grants them a
monopoly to (a) refine the technology, (b) exclude others from making
profits, and (c) make profits for themselves. In light of the Monsanto
Canada case, however, this fails to address the interests of honest but
246. Id. at 171.
247. President Bush's Trade Agenda for 2002: Hearing Before the House Comm.
on Ways & Means, 107' Cong. 23 (2002) (statement of Robert B. Zoellick, U.S.
Trade Representative).
248. Id.
249. See the UK Utility Designs Act, 1843, (protecting "form" and not "function
or principle") 6 & 7 Vict. ch. 65, cited in Janis, supra note 121, at 156 n.25. It is
worth highlighting that the Utility Designs Act embedded a "functional
equivalent" ethos which arguably resulted in effective design protection.
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unfortunate farmers who also have the right to (a) engage in the
legitimate practice of farming, (b) maintain autonomous businesses,
(c) use and dispose of their property as they see fit, and (d) prevent
transgene contamination. Finally, the public shares the right to (a) a
stable and safe food supply and (b) minimal impact level on the
commonly shared environment for producing food. These rights
impose obvious liabilities on the other parties; and these liabilities
cannot, and should not, be left to miscellaneous statutes and courts to
construe when the need arises.
Principle 2: New standards for IP protection of GMCs are needed.
Current IP systems protecting GMCs apply standards which fail to
address the complexities of GMCs. First, one could eliminate patent
protection for GMCs entirely, so there would be no patents to
infringe.250 This, however, fails to provide protection or any incentives
to develop and improve GMCs. Second, one could simply lower the
amount of time during which patents are in force.25' This, however,
fails to address the more fundamental issues of the way in which
patents are issued. Third, one could eliminate TDOE so there are no
excessively broad patent constructions to manage.252 This, however,
simply eliminates the one main semblance of flexibility in the IP
system which can accommodate the unique needs of GMCs. Instead of
employing these current standards, a broader set of guidelines needs to
be developed which can accommodate an analysis of the unique
characteristics of GMCs in order to facilitate comparisons between
inventions within various biotechnological subgroups. Gorton
proposes that a "pyramid test" be introduced - retaining TDOE
though in a more flexible, yet rigorous manner - to begin imbuing a
greater spirit of flexibility into the current system."' In time, this could
be used to help the system evolve even more dramatically.
250. See Paul Blunt, Note, Selective Breeding and the Patenting of Living
Organisms, 48 SYRACUSE L. REV. 1365, 1374 (1998), cited in Gorton, supra note
181, at 343 n.108.
251. See Laura E. Ewens, Note, Seed Wars: Biotechnology, Intellectual Property,
and the Quest for High Yield Seeds, 23 B.C. INT'L & COMP. L. REV. 285 (2000), cited
in Gorton, supra note 181, at 343-344 nn.113-114.
252. Lawrence S. Graham, Note, Equitable Equivalents: Biotechnology and the
Doctrine of Equivalents after Warner Jenkins Co. v. Hilton Davis Chemical Co., 6
J. L. & POL'Y 741, 770 (1998), cited by Gorton, supra note 181, at 344 n.120; see
also Weston, supra note 1.
253. See infra Exhibit 9, outlining the "pyramid" approach to applying TDOC.
Essentially, in comparing two organisms with a given characteristic (such as a
genetically modified gene), the processes in which a DNA fragments or genes were
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Principle 3: New processes for ensuring IP protection GMCs need to
be developed. The current system of IP protection for GMCs relies
simply on patents which are reviewed by courts of general jurisdiction;
however, something else is needed given their complexities. For these
purposes, one can envisage a new system in which (a) judges with
scientific backgrounds are appointed; (b) new notice requirements are
established for public comment; (c) negotiated, contract-based
settlements are increasingly accommodated - and encouraged -
between conflicting parties to avoid expensive, drawn-out, extensive
litigation; and (d) uniform application standards crossing state and
international boundaries are applied.5  In this system, new processes
would accommodate the new standards, and the new standards would
be supported by these new processes. Only in this way can the risk of
the anti-commons, discussed above, be avoided, in turn preventing
"every grain of sand" from systematic ownership. In many ways, this
principle counterbalances the first principle: it is important to
recognize parties' broader sets of rights, though these rights are also
limited. Private property exists, mistakes are made, and developing
255
nations have special needs. Ideas integrating public clearinghouses
on GMCs, public-private partnerships reviewing GMCs, and pre-
market consultations are all possible.
Principle 4: Recognize concertedly that GMCs have a qualitatively
different impact on society than previous inventions. It is essential to
recognize in developing any new system of IP protection for GMCs
that GMCs have an impact on society which differs dramatically from
other inventions - predominantly because GMCs are living
organisms. The impracticalities of labeling are illustrated by the fact
that once seed is released into the environment, humans cannot
created are isolated. They are then identified and compared. Second, their genetic
codes are examined, and it is determined how any given modifications were
inserted into the given organisms. Third, the mechanism by which transcription
occurred and a protein was encoded by the DNA is reviewed. And finally, the
protein's effects on the function of the relevant organisms - as well as products
generated by the genetically modified organisms - are reviewed. "If each level of
the accused organism matches the patented invention, either literally or as an
equivalent, then the accused party is guilty of infringement." Gorton, supra note
181, at 349.
254. Definitions, for example, could be agreed upon - ideally transnationally.
The term "transgenic plant," for example, is vague and might include all plants on
the planet because one could argue that any gene of interest which can be
demonstrated to have been altered is, by definition, transgenic.
255. See Souza, supra note 32, at 138 n.35, quoting FAO, supra note 79.
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control the course of events. Similarly, the process by which GMCs
are developed differs enormously from inventions of the past. Gone
are the days of individual inventors in their living rooms. Large
26corporations and teams of researchers are now the norm. 5  These
"individuals" have different interests and deeper pockets than their
predecessors. The latter is important in adjusting tort liability to
require more stringent standards.257
Principle 5: IP regimes for GMCs must have different theoretical
underpinnings than typical IP systems. On the broadest level, the
theoretical underpinnings of IP regimes for GMCs differ from other
types of property. Kojo Yelpaala, in his telling discussion on the
evolution of IP rights, references a range of property types recognized
in Roman law. Several of these could be applied in developing new IP
regimes for GMCs. Roman law distinguished between (a) things
susceptible to private ownership, though not presently owned (res in
nostro patrimonio) and (b) things not susceptible to private ownership,
so not owned (res extra nostrum patrimonium). This latter category
included (i) things owned by everybody, or common goods (res
communes), (ii) sacred property (res sacrae), (iii) religious property
(res religiosae), and (iv) religious antiquities (res sanctae). Thus, there
were things susceptible to private ownership, though not owned, such
as things governed by "divine law" (res nullius), and there were things
assigned to new categories altogether.258 The time may now be ripe for
creating a new set of property, res physciae (or "scientific biochemical
things"), to which would be associated new sets of legal rights and
responsibilities.
The above five principles are not representative of a given
philosophy, though they address a range of interests which cross many
philosophical lines. Indeed, they are utilitarian in the degree to which
they seek to ensure that biotechnological developments are managed
in ways which maximize the greatest good for the greatest number.259
256. From 1985 to 1995, corporations owned between seventy-three and
seventy-six percent of patents; this increased to seventy-nine percent in 1998
(depending on how one defines "corporation," which could include universities).
National Science Foundation, Industry Technology, and the Global Marketplace,
Chapter 7, available at http://www.nsf.gov/sbe/srs/seindOO/access/c7/c7s3.htm (last
visited Apr. 24, 2004).
257. See Van Cleve, supra note 50, at 306. See generally GUIDO CALABRESI,
THE COST OF ACCIDENTS (1970).
258. Yelpaala, supra note 2, at 132.
259. See generally JEREMY BENTHAM, AN INTRODUCTION TO THE PRINCIPLES OF
MORALS AND LEGISLATION (Clarendon Press, 1879) (1789).
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They are also Kantian in the degree to which they posit certain
categorical imperatives (i.e., that GMCs are unique "inventions" which
deserve special treatment). 260 Third, they are libertarian, in the degree
to which they suggest that individuals should be allowed to research,
investigate, and develop new technologies as much as possible, albeit
under the watchful eye of affected parties.261 Finally, they abide by
principles akin to economic rationalism, in that they view GMCs as a
form of property and as "instrument[s] for achieving . . . concrete
societal objectives," with efficiency (defined broadly) as an implicit
object and purpose of IP rights.262 Lines need to be drawn, and lines
can be drawn, as illustrated by the global rejection of the "Terminator
Seed" technology developed by Monsanto26 and increasing attempts to
bound IP claims.2 4
260. See generally IMMANUEL KANT, GROUNDWORK FOR THE METAPHYSICS OF
MORALS (Allen W. Wood ed., trans., Yale University Press, 2002) (1785).
261. See generally JOHN LOCKE, POLITICAL ESSAYS (Mark Goldie ed.,
Cambridge University Press, 1997) (1690).
262. See id. at 180-81. There is a problem with using the word "efficiency" since
biochemical patents are often linked to processes and these processes can often be
hard to imitate in scope (in other words, one cannot obtain ownership over literally
all the processes which lead from A to B in a given genetic manipulation since
these processes incorporate countless biological, chemical, and physical steps on
the cellular, atomic, and subatomic levels).
263. Yelpaala, supra note 2, at 208. The "Terminator Seed" technology was
resoundingly rejected because of the public policy implications of the technology
and illustrate the degree to which IP rights for GMCs already transcend traditional
IP boundaries. Indeed, critics felt that an invention that "has as its motive, explicit
or implicit, the destruction of a source of human ingenuity, the spread of
knowledge, and the ability to tinker with ideas in nature should not be patentable."
Id. There was also the pointlessness of IP protection given the fact that the
invention allowed its holder to create a natural 'absolute monopoly' not in need of
any protection from humans.
264. Consider, for example, the increasingly common arguments that elements
of an IP claim for GMCs should
extend no further than ... the composition of a genome constituting a
transgene, inserted by genetic manipulation techniques, which is
expressed. The legal estate created by the granting of the claim is
therefore to either an (a) expressed transgene, inserted into the plant
genome by genetic manipulation techniques or (b) at most, to the
composition of the plant genome with the expressed transgene inserted by
genetic engineering techniques. The exclusive interest of the patentee is
then the right of the patentee to exclude others from (1) making, (2) using,
(3) selling, or (4) offering to sell a genome constituting an expressed
transgene, inserted by genetic engineering techniques.
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IV. CONCLUSION
Ensuring that the benefits of GMCs are best harnessed - and
pitfalls avoided - will require a significant dose of will and creativity.
It will imply significantly altering the ways in which IP rights for GMCs
are distributed and managed, and it will transcend national
borderlines. It will require significant investment, as well as political
capital. And it will require imagination and inspiration, particularly in
different forms of private-public partnerships if the public's fears
increasingly associated with GMCs265 are to be allayed.
Despite these seemingly highfalutin goals, resolution is possible, if
not inevitable. This article proposes, as a start, five guiding principles
which stem from the current GMC debate, particularly applicable to
countries faced with (a) developing new IP systems, such as Australia,
and (b) wresting with management of current IP systems, such as
Canada. There is no reason to believe that novel solutions cannot be
unearthed which also allow legislatures and international bodies to
transcend their current approaches to the ways in which IP laws are
made and adjudicated. GMCs are unique; and the legal protection
afforded them must - and ultimately will - reflect this.
Busch, supra note 85, at 102 (emphasis and alphanumeric notations added).
265. See infra Exhibit 15, supra note 82.
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applied to GMCs.
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Exhibit 1
AUSTRALIA IS THE LEAST DENSELY POPULATED COUNTRY ON EARTH*
No. of persons per square km, 2000
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* Australia's Bureau of Statistics reported Australia's population at
19,815,822 as of 10:21am (NSW EST) on March 2003, making it still the least
densely populated country on earth; for up-to-the-second statistics and the
population clock, see http://www.abs.gov.au/Ausstats. Source: World Bank; The
Economist; South Australia Geological Society; Australian Bureau of Statistics; South
Australia Museum; research conducted by C. Scott L6pez
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Exhibit 2
MOST POLLEN TRAVELS A COMPARATIVELY SHORT DISTANCE
FROM ITS SITE OF ORIGIN
Percentage of ALS herbicide-resistant individuals in seed from nonresistant
varieties vis-td-vis distance from source fields*
0.2-
0.15-
0.1-LL
U,'
3000Dt e0
Distance (m)
* Three individual samples were collected per field, with 190 individual
collection locations. Source: Mary A. Rieger et al., Pollen Mediated
Movement of Herbicide Resistance Between Commercial Canola Fields,
296 Sct. 2386. 2387 (2002).
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Exhibit 3
DIFFERENT VARIETIES OF SEEDS TEND TO SPREAD OUT MORE
WIDELY THAN OTHERS
Percentage of ALS herbicide-resistant individuals in sink fields, by seed
varieties; number of fields screened are indicated above each bar
S0.04
0.03
0.02
0.01
Source: Mary A. Rieger et al., Pollen Mediated Movement of Herbicide Resistance
Between Commercial Canola Fields, 296 Sci. 2386, 2387 (2002); selected by C.
Scott L6pez.
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Exhibit 4
VARIOUS METHODS HAVE BEEN USED TO INDUCE
MUTATIONS IN KEY CROPS
Key crops, cultivar names, and major methods used to induce mutations
Irop 11cutuvar Name iMethod Used to Induce Mutation
ice IlCalrose 76 71gamma rays
ea bv sodium aide
ILews 1termal neutrons
oats Iviamo-x I-rays
Io Red Iermal neutrons
grapeuStar Ruy Itermai neutrons
ITifeagie Igamma rays
tgurmuda grass IIgenh 1gamma rays
uu s T 94 gamma rays
ITr y 11 Igamma ra
ic cube Il methanesulphonate
eucea MiGreen I1 methanesulphonate
commron bean [saae V ray
Ifac I Praimn Petite J1ermal neutrons
gss TXSA 8202 gamma raysS gst n gross 1 gamma rays
Source: Transgenic Crops Resource Guide, available at
http://www.colostate.edu/programs/lifesciences/TransgenicCrops/history.html;
research by C. Scott L6pez.
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Exhibit 5
INCREASED R&D INVESTMENTS HAVE MIRRORED THE GROWTH IN
TRANSGENIC CROPS - PARTICULARLY FOR SOYBEANS
Pharma & biotechnology Area of transgenic crops world-wide, 1996-2001
R&D spending, 1994-2001 Millions of hectares, sorted by type of crop
Pounds Sterling, billions
1.
Soyean 
25 Corti
20 TobaCto
Cotton
to Tonato
-Ptitato
1990 1997 199 1999 2000 2001
-n i
Area of transgenic crops world-wide, 1995-
ii 2002
Millions of hectares, sorted by
* industrial and develonini, countries
60
50
TotaL
40
94 95 96 97 98 99 00 01 cntriels
Year 20
10
Developing 1
". 0
1995 96 97 98 99 2000 01 02
Source: SCRIP Reports, Transgenic R&D Compendium, available at
http://www.amersham.co.uk/investors/AR01/rep27.html; Transgenic Crops Resource
Guide, available at
http://www.colostate.edu/programs/lifesciences/TransgenicCrops/current.html;
Survey of Technology Insert, THE ECONOMIST, Mar. 29, 2003, at 16 following 50;
research and selections by C. Scott L6pez.
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Exhibit 6
THE UNITED STATES CURRENTLY LEADS THE WORLD IN
TRANSGENIC CROP PRODUCTION
Transgenic Crop Production, by country, 2000
Area planted in 2000
(millions of acres)
74.8
24.7
7.4
1.2
0.5
0.4
minor
minor
minor
minor
minor
minor
minor
Crops grown
soybean, corn, cotton, canola
soybean, corn, cotton
soybean, corn, canola
cotton
corn, cotton
cotton
cotton
corn
soybean, potato
corn
com
corn
soybean
Source: Transgenic Crops Resource Guide, available at
http://www.colostate.edu/programs/lifesciences/TransgenicCrops/current.html;
research by C. Scott L6pez.
Country
USA
Argentina
Canada
China
South Africa
Australia
Meco
Bulgaria
Romania
Spain
Germany
France
Uruguay
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Exhibit 7
THE GENETIC MODIFICATIONS CAN-UNSURPRISINGLY-HAVE
DRAMATIC EFFECTS
Photographs of corn and soybean varieties with genetic modifications
(genetically modified species on left; wild-type on right)
Corn Soybeans
4 b t;
F A
Source: Transgenic Crops Resource Guide, available at
http://www.colostate.edulprograms/lifesciences/TransgenicCrops/current.html;
research by C. Scott Lpez.
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Exhibit 8
THE GENETIC CODE ALLOWS FOR HUGE NUMBERS OF
NUCLEOTIDE SUBSTITUTIONS WHICH DO NOT RESULT IN
NECESSARY AMINO ACID (AND RESULTING PROTEIN)
MODIFICATIONS
Amino acids (short forms) coded by different combinations of nucleotides (i.e., T,
C, A, and G)
TTT Phe [F]
TTC Phe [F]
T
TTA Leu [L]
F TTO Leu [L]
i
r CTT Leu [L]
s C CTC Leu [L]
t CTA Leu [L]
CTO Leu [L]
0 ATT lie [I]
S
i A ATC Ile [I]
t ATA Ile [I]
i ATO Met [M]
0
n GTT Val [V]
OTC Val [V]
GTA Val [V]
GTO Val [V]
TCT Set [3]
TCC Set [S]
TCA Set [S]
TCO Set [S]
CCT Pro [P]
CCC Pro [P]
CCA Pro [P]
CCO Pro [P]
ACT Thr [T]
ACC Thr [T]
ACA Thr [T]
ACG Thr [T]
OCT Ala [A]
_CC Ala [A]
OCA Ala [A]
GCO Ala [A]
TAT Tyr M1
TAC Tyr [Y]
TAA Ter [end]
TAG Ter [end]
CAT His [H]
CAC His [H]
CAA Gin [Q]
CAG Gln [Q]
AAT Asn [N]
AAC Asn (N]
AAA Lys [K]
AAG Lys [K]
OAT Asp [P]
GAC Asp []
OAA Olu [E]
GAG Olu [E]
Source: STRYER ET AL., BIOCHEMISTRY (5' ed. 2002); research by C. Scott
L6pez.
TOT Cys [C]
TGC Cys [C]
TOA Ter [end]
TOO Tr [W]
COT Arg [R]
COC Arg [R]
COA Arg [R]
COO Arg [R]
AOT Set [S]
AGC Set [S]
AGA Arg [R]
AGG Arg [R]
GOT Oly [G]
GGC Oly [0]
GOA Gly [0]
GGO Oly [0]
T n
C
A
G
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Exhibit 9
ONE METHOD OF ADDRESSING PROBLEMS WITH THE DOCTRINE
OF EQUIVALENTS IS BY USING A "PYRAMID" APPROACH TO
ASSESS POSSIBLE PATENT INFRINGEMENTS
Graphic representation of the 'pyramid' approach applied to genetically modified
crops
Source: Alexis Gorton, Edible Equivalents: An Increase in Patent Protection
for Genetically Modified Organisms, 9 WASH. U. J. L. & POL'Y 321, 352 (2002);
research by C. Scott L6pez.
Key ideas:
(1) The Doctrine of
Equivalents will be
applied by
searching for
insubstantial
changes at each
level of creation
required to develop
a GMO.
(2) At each level there
are less possible
ways to achieve the
desired result; thus,
the range of
equivalents will
depend on how
much latitude exists
to allow
competitors to
design around the
patent.
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Exhibit 10
StarLinkTM CORN, CONTAINING THE GENE Cry9c, WAS AT THE
CENTRE OF A MAJOR PUBLIC RELATIONS FIASCO
Host Organism / Zea, mays L, (Maize) Starlink'
Vaiety
Trait Resistance to European corn borer
(Ostrna nubaft); phosphinothricin
(PPT) herbidde tolerance,specifically glufosinate mmonium.
Trait Introduction Hioporobde bombardment of plant
Method cells or tissue
Proposed Use production fmeal and silage for
livestock feed, and producto forindustial applications. This materi.al
will not be grown outside of thenormal production area for maize.
Company Aventis CropSdence
Information
Modificabhon Method
CBH-351 maize was produced by biolistc transformaton of the backcrossed hybid
maize line (PA91 x H9t) x H99 with two pUCit based plasmids, PRSVA9909 and
pDE1Ot. Both plasmids contained the modified cryx gene and the bar gene,
respectively, engineered for enhanced expression in plants. The crygC and bar genes
were fused to noncoding regulatory sequences that enabled them to be expressed at
high levels, constitovely throughout most of the plant. Spefically, the expression f
the modified c'y9C gene was regulated by the promoter and terminator sequences from
the 35S transcrnpt of CattV, along with the leader sequence of the cab22L gene from
petunia. The expression f the bar gene was also directed by the 35S CaMV promoter
along with the 3' untranslated region from the nopaline synthase (nos) gene from A.
tumefaiens which is involved in transaption termination a d polyadenylation. Although
most of these regulatory regions were derived from plant pathogens, the regulatory
sequences cannot cause plant disease by themselves orwith the genes that they are
designed to regulate. Additonal genetic elements present on the transforming plasmids
included the ampicillin resistance gene beta-lactamase (b/a) and the origin of replicaton
(on) both from the enteric bacterium, EsciendAa cot. Both were introduced into CBH-
351 maize, however these elements are nonfunctional in plants. The bta gene was
present on the plasmids onfy as a selectable marker to detect transformed E. coli host
bacteria.
Source: Essential Biosafety website, available at
Summary of Introduced Genetic Elements
Code Name
bar phosphinothridn H-
acetyltransferase (S.
oc9* crygc deah"
endotoxin (B-doobs
Type Promoter, Terminator Copies Form
other
HT CoMV 35S A. tvnnefaaisceo o4
nopalim
synhase (ces)
3'-
polyadenylabon
signal
IR CaMV 35S CaMV 35S poly =1 Truncat
; leader (A) signal N'C-
ronniaeooia suasp. sequence of
TAIoida) the cab22L
gene of
Petonia
hybridia
(chloroplast
aransit
peptide)
A beta latamase SM bacterial
promoter
Characteristics of Zea mays L. (Maize)
Center of Reproduction Toxins
Origin
Mesoamercan Cross-poltinaon via wind- Ho endogerous
region, ow bore polen is limited, pollen toxins or
Mexio and viability is about 30 minutes. ignificant levels
Central America Hybndtizaon reported with of antinuritional
teosinte speces and rarely factors,
aiti members ofthe genus
Tripsacum.
Donor Organism Characteristics
Latin Name
stmotomyce
hygroscop's
subsp. fwho i
Gene Pathogenicity
bar S. hygmscopkiis is ubiquitous in the soil and them have been no
reports of adverse affects on humans, animals, or plants.
arfyc While target insects are susceptible to tral doses of & proteins,
no evidence of acute toxiity in laboratory mammals, birds, or
non-tartet benefldal insects has been reported. The CrygC
protein is resistant to heat and proteolytic degradation and may
have aleroenic potental
http://www.essentialbiosafety.info/dbase.php?action=ShowProd&data=CBH351&frma=LONG;
research by C. Scott L6pez.
ed
Not
expressed
in plant
tssues
Allergenicity
Although some
reported sass. of
maize allergy, protein
(s) responsible have
not been identfied.
carmnea
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Exhibit 11
WET-MILLING CORN IS THE MOST POPULAR MEANS OF
PROCESSING CORN WORLDWIDE
Type of corn used worldwide, by milling
process
Percent
Wet milling process
Cam - among
.- 4 m.i.
AW Ekd WOO hnkf
FhAd t DqG hU i 2, WNdl r.W sm am Cbmk
.
I
Protein content & uses of wet
milled corn
Friolo ApprnimIte Prct Proti Um
Conent
Stp LiI- 45-4q% Pmcm AirJ Fmd
ComrGam 20% Anid F*d
BO~fmooe 18-M2%pwooi kn rd
Giuto kid 66A Frotln A Frd
starch 0.3-0.35% Prtin n=odied com
da
SYTUP Not Dtletbr pooodn"r,
mode om Armch) com p, coo
.Ake Dtlectable' p extrshi(a fiocso corn
Corna 0ot D tbl k rsad
'Sor: iotcdl992; Kyd Brmco, 200D
SMoot wo0= d for aonm f moe toe r Swe  =Wwa ol mco z6 and
i amWto orid ofohwpoh tD mx drw eebItprocooas cniks r
Section Il. B.
C pom i n no5t 0 bo iman into high o'oo cmd % rcmiomoes
'Cordon proecin of COroM coot eOrc nrro protei
Source: U.S. Environmental Protection Agency, White Paper on the Possible
Presence of Cry9c Protein in Processed Human Foods Made from Food Fractions
Produced Through the Wet Milling of Corn (Washington, DC, EPA, 2002),
available at http://www.epa.gov/scipoly/ sap/2001/july/wetmilling.pdf;
research by C. Scott L6pez.
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Exhibit 12
WET MILLING CORN IS ONE WAY TO REDUCE THE AMOUNT OF
Cry9c PROTEIN-THEREBY ELIMINATING FEARS OF ALLERGIC
REACTIONS FROM HUMAN CONSUMPTION
Estimated upper bound exposure to Cry9c protein for various population
groups assuming food containing corn starch was made from grain containing
1.2% StarLinkTm corn
Percentiles in percent; other figures in micrograms
Group Potential Daily Exposure of Cry9C Protein froim Corn Starch
Upper Bound Exposure for 1999 (1.2%)
Percentile: 95 99 99.5
US Population 0.00387 ug 0.01103 ug 0.0 1567 ug
Infants 0.00135 ug 0.00213 ug 0.00232 ug
Children I to 6 yrs 0.00116 ug 0.00290 ug 0.00387 ug
Children 7 to 12 yrs 0.00 174 ug 0.00484 uI 0.00639 ug
Estimated upper bound exposure to Cry9c protein for various population
groups assuming food containing corn starch was made from grain tested by
GIPSA guidelines and containing 0.125% or less StarLinkTm corn
Percentiles in percent; other figures in micrograms
Group Potential Daily Exposure of Cry9C Protein fron Corn Starch
Upper Bound Exposure (0.125%)
Percentile: 95 99 99.5
US Population 0.0003249 ug 0.0009261 ug 0.0013161 ug
Infants 0.0001137 ug 0.0001785 ug 0.000195 ug
Children I to 6 yrs 0.0000975 ug 0.0002436 ug 0.0003249ug
Children 7 to 12 yrs 0.0001461 ug 0.0004062 ug 0.0005361 ug
Source: U.S. Environmental Protection Agency, White Paper on the Possible
Presence of Cry9c Protein in Processed Human Foods Made from Food Fractions
Produced Through the Wet Milling of Corn, at tbls. 5-6 (Washington, DC, EPA,
2002), available at http://www.epa.gov/scipoly/ sap/2001/j uly/wetmilling.pdf;
research by C. Scott L6pez.
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Exhibit 13
POSSIBLY PATENTABLE ITEMS CAN BE CLASSIFIED IN ONE OF
3 KEY WAYS
Unrestricted
Ownership
Universe: Universe of Ideas In biotechnology.
Norm i: That which cannot be owned Is not patentable.
Norm 2: That which can be owned may nevertheless not be patentable.(a) Specific exclusion.(b) Exclusion through patentability criteria.
Norm 3: That which Is patentable may nevertheless not be patented on public policy grounds.
Source: Koj o Yelpaala, Owning the Secret of Life: Biotechnology and
Property Rights Revisited, 31 MCGEORGE L. REV. 111, 194 (2000); research
by C. Scott L6pez.
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Exhibit 14
MONSANTO HAD EXPANDED ITS BIOLOGICAL RESEARCH
INTERESTS IN MANY AREAS BY THE MID-90s
Source: Kojo Yelpaala, Owning the Secret of Life: Biotechnology and
Property Rights Revisited, 31 McGEORGE L. REV. 111, 168 (2000); research
by C. Scott L6pez.
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Exhibit 15
MOST COUNTRIES SOON JOINING THE EU DO NOT WANT GM
PRODUCTS DISTRIBUTED
EC Eurobarometer Survey of countries due to join the EU in 2004 re:
attitudes towards GM food
"I do not want this type of food.
EU candidate countries, %, November 2002
DISAGREE 4 0- AGREE
25 0 2 3 50 75 100
Latvia
SLovenia
Cyprus
Estonia
Hungary
Romania *
Turkey*
Average
Potand
Lithuania
Slovakia
Czech Rep
Butgaria*
Ma Lta
Source: Survey, Genetically Modified Food, ECONOMIST, Apr. 5,
2003, at 98; research by C. Scott L6pez.
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